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Summary
Idiopathic Pulmonary Fibrosis (IPF) is a progressive interstitial lung disease of 
unknown etiology associated with high morbidity and mortality, and further 
characterized by abnormal alveolar epithelial and fibro-proliferative responses, 
excessive extra-cellular matrix deposition, patchy inflammatory infiltrations and 
progressive loss of normal lung structure. At present there is no demonstrably 
effective therapy for blocking or reversing the progression of the disease. This 
situation demands a better understanding of the molecular and cellular 
mechanisms involved in the pathogenesis of IPF.
Current evidence suggests a role of cyclic guanosine monophosphate
phosphodiesterases (cGMP-PDEs) in the pathogenesis of various proliferative lung 
diseases, including IPF. Lung PDE6 expression and function has received little or 
no attention. The present study aimed to characterize (i) cGMP PDEs profile in IPF, 
(ii) PDE6 subunits expression in human lung, (iii) PDE6 subunits expression and 
alteration in IPF and (iv) functionality of the specific PDE6D subunit. The 
experiments were carried out with human lung samples from donors and IPF 
patients. RT-PCR analyses from donor and IPF human lungs revealed up-
regulation of PDE1A, PDE10A and PDE11A in the IPF lungs and expression of 
PDE6 subunits mRNA transcripts in human lungs. Westernblot analysis showed 2-
fold up-regulation of PDE6A and PDE6B, and 2-fold down-regulation of PDE6D 
and membrane localization of PDE6G in the IPF lungs as compared to the donor 
lungs. Immunohistochemical analysis showed alveolar epithelial localization of the 
PDE6 subunits. RT-PCR analysis from donor and IPF-derived human primary 
alveolar type (AT) II cells confirmed the cellular localization of the PDE6 subunits 
and the down-regulation pattern of PDE6D. Further, siRNA-mediated PDE6D 
knockdown and an ectopic PDE6D expression in A549 cells demonstrated the 
modulatory effects of PDE6D on alveolar epithelial cell (AEC) proliferation. 
Additionally, we showed that these effects specifically involve ERK phosphorylation. 
Collectively, we report (i) mRNA expression profile of cGMP PDEs in IPF, (ii) 
previously unrecognized PDE6 expression in human lungs, (iii) pronounced 
alterations of PDE6 subunits in IPF-derived lungs and (iv) characterize the 
functional role of PDE6D in AEC proliferation.
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Zusammenfassung
Die idiopathische pulmonale Fibrose (IPF) ist eine progressive interstitielle 
Lungenerkrankung unbekannter Ätiologie, assoziiert mit hoher Morbidität und 
Mortalität. IPF charakterisiert sich weiterhin durch abnormale epitheliale und fibro-
proliferative Reaktionen, exzessive Ablagerung extrazellulärer Matrix, 
ungleichmäßige inflammatorische Infiltrate und einen progressiven Verlust der 
normalen Lungenstruktur. Gegenwärtig existiert keine nachweislich effektive 
Therapie zur Beeinflussung des Krankheitsverlaufs. Diese Tatsache unterstreicht 
die Notwendigkeit für ein besseres Verständnis der molekularen und zellulären 
Mechanismen, die  in der Pathogenese der IPF involviert sind.
Neue Studien weisen auf eine Rolle der Phosphodiesterasen des zyklischen
Guanosinmonophosphats (cGMP-PDEs) an der Pathogenese von 
unterschiedlichen  Lungenerkrankungen, einschließlich IPF. Allerdings wurden die 
Expression und Funktion der Lungen-Phosphodiesterase 6 (PDE6) bisher wenig 
untersucht. Die vorliegende Studie hat sich Folgendes zum Ziel gesetzt: (i) die 
Charakterisierung der Expressionsprofile der cGMP-PDEs bei IPF in der Lunge, 
(iii) die Charakterisierung der Expression der PDE6-Untereinheiten in der Lunge, 
(iii) die Untersuchung der Expressen der PDE6-Untereinheiten bei IPF und (iv) 
charakterisierung der Funktion der PDE6D-Untereinheit.
Untersucht wurde Lungenmaterial von gesunden Probanden und IPF-Patienten. 
Durch RT-PCR wurde eine Hochregulation der Gen-Transkription von PDE1A, 
PDE10A und PDE11A in IPF-Proben sowie eine Basis-Transkription  der PDE6-
Untereinheiten nachgewiesen. Western-Blot-Experimente zeigten eine 
Hochregulation von PDE6A und PDE6B ums Zweifache und eine gleichstarke 
Abschwächung von PDE6D bei IPF im Vergleich zu gesunden Probanden. 
Darüber hinaus wurde eine Membranlokalisation der PDE6G bei IPF festgestellt. 
Die immunhistochemischen Untersuchungen zeigten die Lokalisation der PDE6-
Untereiheiten im alveolaren Epithel. RT-PCR-Analysen von primären Typ II 
alveolaren Zellen (ATII) von Probanden und IPF-Patienten bestätigten die 
Anwesenheit der PDE6-Untereinheiten und die Herunterregulation  von PDE6D bei 
IPF. Durch siRNA-Knockdown von PDE6D und ektopische Expression von PDE6D 
in der A549 Zellinie wurden die modulierenden Effekte dieser Untereinheit auf die 
Proliferation von alveolaren Epithelzellen (AEC) demonstriert. Es konnte auch 
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gezeigt werden, daß diese Effekte spezifisch die Phosphorylierung von ERK 
beeinflussen. 
Zusammenfassend, wurden in dieser Arbeit (i) die Expressionsprofile der 
Phosphodiesterasen des zyklischen Guanosinmonophosphats (cGMP-PDEs) in 
IPF-Lungengewebe erstellt. (ii) eine bis dato nicht beschriebene Expression von 
PDE6 in der humanen Lunge konnte nachgewiesen werden. (iii) die Veränderung 
der PDE6-Espression in IPF-Lungenproben und (iv) die Rolle der PDE6D-
Untereinheit bei der Proliferation von AEC wurden analysiert.
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I. Introduction
1. IPF.
IPF, also known as cryptogenic fibrosing alveolitis (CFA) is a distinct subgroup of 
idiopathic interstitial pneumonias (IIPs). It is a terminal condition in most patients, 
characterized by aberrant scarring of the lung tissue and dramatic loss of 
respiratory function secondary to AEC damage, aberrant fibroblast accumulation, 
excessive collagen deposition, and matrix remodeling [1-3]. As the name implies 
IPF is a disease of unknown origin (from the Greek words "idio"- peculiar or 
unusual, "pathy"–illness, and “kryptos”-hidden). Significant numbers of factors, 
however, are reported to consistently increase the risk for IPF: 
Occupational and environmental exposures: such as mineral dust 
(silica/silicates), metal dust (steel, brass, and lead), wood dust (specifically pine), 
stone or sand dust, farming, cattle or livestock handling and use of wood fires are 
considered substantial risk factors for IPF development [4-7].
Cigarette smoking: is identified as a potent risk factor with an odds ratio 
increasing with the pack/year of smoking [8, 9]. 
Asymptomatic gastroesophageal reflux: a small study produced evidence that 
asymptomatic gastroesophageal reflux occurs more frequently in patients with IPF
than in patients with other interstitial lung diseases and thus deserves to be 
considered as a possible etiological feature of IPF [10]. 
Chemotherapeutic agents and radiation: are considered to induce high 
incidence of pulmonary complications, pulmonary fibrosis being one of them [11-
14]
Infectious agents: a high incidence of Epstein-Barr virus (EBV) [15, 16], influenza 
[17-20], cytomegalovirus (CMV) [21], and hepatitis C [22, 23] infections is reported 
in patients with IPF. The etiologic relevance of these reports, however, remains 
elusive [24, 25]. 
Heredity factors: familial cases of IPF are reported as well and are considered to 
be inherited as an autosomal dominant trait with variable penetrances [26-29]. 
Several investigators have reported an association between IPF and 1 -
antitrypsin inhibition (Pi) alleles present on chromosome 14 [30-32]. Thomas et al.
have identified a mutation in the prosurfactant protein-C (proSPC) gene
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(leucine→glutamine) in a kindred of patients with familial IPF, resulting in an 
improper proSP-C folding and processing in ATII cells [33]. A recent and intriguing 
report described polymorphisms of hTERT and hTR genes regulating telomere 
length in a cohort of patients with familial IPF. These genes have a pivotal role in 
controlling cell death and aging and therefore are of particular importance [34].
IPF is a devastating disease with a very poor prognosis and currently unavailable 
drug therapy. The average survival rate of IPF patients is approximately three to 
five years from the onset of the symptoms [35-37]. Some predominance in males is 
observed [5, 35]. Eventhough IPF is considered a disease of the elderly people; 
cases are reported in young children and infants as well [36-38]. Recent reports 
suggest that IPF is substantially more prevalent than previously considered [39-41].
The notably malignant pattern of IPF compared to the other subgroups of IIPs, 
demands a better understanding of what constitutes IPF.
1.1. Classification.
Hamman and Rich [42] are often credited for the first description of unexplained 
interstitial pneumonia in 1944. Nevertheless, it was Scadding and Hinson, in 1967, 
who actually defined IPF for what it is known today [43]. The growing body of 
information on IIPs was first systematized by Liebow and Carrington on the basis of 
specific histologic patterns [44]. Subsequently, the Liebow-Carrington classification 
scheme has undergone numerous revisions [43, 45-50]. The morphological 
spectrum of IPF in these revised classification schemes, however, still 
encompassed several histological patterns. There was a need IPF to be more 
narrowly defined as a distinct clinical entity. In 2002, an international consensus 
statement [51] has proposed the classification of IIPs into seven distinct subtypes: 
usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), 
respiratory bronchiolitis-associated interstitial lung disease (RB-ILD), desquamative 
interstitial pneumonia (DIP), acute interstitial pneumonia (AIP), lymphoid interstitial 
pneumonia (LIP) and cryptogenic organizing pneumonia (COP). The classification 
and the most contrasting histological features of the seven distinct IIPs categories 
are given in Table I (appendix).
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1.2. Definition.
Of these IIPs entities, IPF is defined as a specific form of chronic fibrosing 
interstitial pneumonia, limited to the lung, and associated with the histopathological 
pattern of UIP on open or thoracoscopic surgical lung biopsy [51]. Henceforth, the 
two terms IPF and UIP are often used in an analogus manner. 
1.3. Histopathology.
Figure 1. Histopathology of IPF.
a) Hematoxylin&Eosin (H&E) staining showing the normal lung structure in a donor 
subject, b) H&E staining showing the distorted lung structure in a IPF patient, 
magnification 50x. Author’s slide.
The cardinal features of UIP are temporal heterogeneity, fibrosis with variable 
numbers of fibroblastic foci, honeycomb changing, interstitial inflammation and 
vascular remodeling [52]. These histopathologic changes affect mostly the 
peripheral subpleural parenchyma. 
Heterogeneity: is the most striking histological feature of UIP. Areas of normal 
lung structure (lower left quadrant in Figure 1b) contrast with areas of extensive 
fibrosis honeycomb changes, interstitial inflammation and vascular remodeling 
(right quadrant in Figure 1b) [1]. 
Fibrosis: areas of active fibrosis are characterized by clusters of fibroblasts/ 
myofibroblasts observed at the border between fibrotic and normal lung, termed 
fibroblastic foci (square box, Figure 1b) [2]. Alveolar epithelial injury with 
hyperplastic type II pneumocytes is often seen in these areas [53]. The fibrotic 
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zone usually shows temporal heterogeneity with dense acellular collagen bundles 
(“old fibrosis”) and scattered fibroblastic foci, signifying a progressive process.
Honeycomb changes: these are enlarged cystic airspaces, filled with mucin and 
lined by bronchiolar and bronchial epithelium type II pneumocytes and occasionally 
metaplastic squamous epithelium (Figure 5b) [54]. The honeycomb cysts are 
separated by thick walls, which contain collagen with varying degrees of 
inflammation. Smooth muscle cell hyperplasia is commonly seen in the zones of
honeycombing [47]. 
Inflammation: the inflammatory component is typically mild to moderate, patchy 
and consists primary of lymphocytes, plasma cells, and macrophages. Other 
inflammatory cells such as neutrophils and eosinophils may be present at low 
abundance. The inflammation occurs mainly in areas of collagen deposition or 
honeycomb lesions, and rarely in otherwise unaltered alveolar septa [2]. 
Vascular remodeling: shows a heterogeneous pattern with both areas of vessel 
ablation and other areas of neovascularization. Vessel ablation is detected within 
the fibroblastic foci and in the areas of honeycombing [55-61].
It should be mentioned, however, that the histological features of UIP described 
above overlap with the histological features observed in asbestosis, chronic 
hypersensitivity pneumonitis and collagen vascular disorders [2]. Accumulating 
evidence suggests as well coexistence of UIP and other IIPs like NSIP and DIP in 
lung biopsies and lung explants from IPF patients [62-65]. 
1.4. Pathogenesis.
The exact mechanisms underlying the pathogenesis of IPF remain enigmatic. For 
the past three decades, a substantial body of research has been conducted in 
understanding the triggering mechanisms of fibrosis in IPF. From these attempts, 
three major hypotheses have emerged. 
The inflammation hypothesis: is based on the idea that injury/inflammation 
precedes the fibrotic response in IPF (Figure 2a) [66, 67]. A support to this 
hypothesis was suggested by the presence of interstitial and alveolar inflammatory 
cells as well as the super-physiological expression of pro-inflammatory cytokines 
such as interleukin (IL)-1, transforming growth factor (TGF)- and tumor necrosis 
factor (TNF)- in the lungs of patients with IPF [66, 68]. In addition, immune 
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deviation towards a T-helper type 2 (Th 2) cytokine profile (IL-4, IL-5, IL-10, IL-13), 
favouring a fibroproliferative response has been shown to predominate in the lungs
of patients with IPF [69, 70]. Along with that, Kolb et al. have demonstrated that at 
least in animal model inflammation induced by transient over-expression of IL-1 is 
followed by remodeling and fibrosis [71]. It has become evident, from multiple 
sources, however, that inflammation may not be a key feature in IPF [1].
Inflammatory cells and intra-alveolar macrophage accumulation do not depict the 
major histological findings in IPF. A mild-to-moderate alveolitis is found either in 
early or late disease stages [47]. Experimental models and some human diseases 
showed that inflammation is not required for the development of a fibrotic response
[72-74]. Clinical measurements of inflammation markers, either cellular or acellular, 
either in blood or in bronchoalveolar lavage (BAL) fluid, fail to correlate with stage 
and/or outcome of the disease [75, 76]. And mostly, potent and long-term anti-
inflammatory and/or immunosuppressive therapies do not improve disease 
outcome [1]. Henceforth, an alternative hypothesis has been advocated.
The abnormal wound healing hypothesis: is suggested by Selman et al. through 
an extensive study of the literature. It states that IPF represents a form of abnormal 
wound healing process in the lung and brings into focus the epithelial-
mesenchymal interplay. According to this hypothesis repetitive episodes of acute 
lung injuries result in an AECs damage and activation. AECs secrete multiple 
cytokines and growth factors such as platelet-derived growth factor (PDGF), TNF-
α, TGF-, endothelin-1 that provoke fibroblast migration, proliferation, and 
transdifferentiation into myofibroblasts. The myofibroblasts in return induce: (i) 
epithelial cell apoptosis (Fas ligands); (ii) angiogenesis [vascular endothelial growth 
factor (VEGF), fibroblast growth factor (FGF)]; (iii) basement membrane disruption 
(gelatinases A and B). This signaling interplay results in excessive and disordered 
collagen matrix remodeling, impaired fibrinogenesis/ fibrinolysis, failure of re-
epithelialization and culminates in aberrant remodeling of the lung parenchyma 
(Figure 2b) [3, 77].
The multiple hit hypothesis: is proposed in the literature most recently. It 
presents an attractive unified hypothesis, postulating that IPF develops as a 
consequence of abnormalities occurring in multiple biological pathways that affect 
both wound repair and inflammation (Figure 3c). This hypothesis is evidenced by 
oligonucleotide microarray data, showing an IPF-gene specific pattern, 
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characterized by up-regulation of genes indicative of ongoing both tissue 
remodeling and inflammatory processes: smooth muscle markers, extracellular 
matrix proteins, proinflammatory cytokines and antioxidants, and immunoglobulins 
[78]. In line, a recent multicenter high-resolution computer tomography (HRCT) 
study revealed that architecture distortion (lower-lung honeycombing, upper-lung 
irregular lines) and inflammation (significant mediastinal adenopathy) are the most 
prominent radiological abnormalities in IPF [79]. The speculated redundancy in IPF 
aetiology (aforementioned) is of further support to this notion.
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Figure 2. Hypothetical models of IPF pathogenesis.
a) Inflammation hypothesis, b) Aberrant wound healing hypothesis, c) Multiple hit 
hypothesis, PDGF platelet-derived growth factor, TNF-α tumor necrosis factor- α, 
TGF- transforming growth factor -, ET-1 endothelin-1, FasL Fas ligand, VEGF
vascular endothelial growth factor, FGF-2 fibroblast growth factor, CTGF
connective tissue growth factor, Th1/2 T helper cells 1/2, PGE2 prostaglandin E2, 
IFN- interferon-, summarized from [3, 80, 81]. The figure is author’s design.
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1.5. Role of AECs in IPF pathogenesis. 
Several lines of evidence suggest the role of AECs in the pathogenesis of IPF. 
Namely, upon injury (associated with fibrosis) AECs display (i) marked 
ultrastructural alterations: hyperthrophy and hyperplasia, aberrant cuboidalization, 
occurance of intermediate cells (ii) marked phenotypic alterations: expression of 
cytokeratin epitopes usually not present in the alveolar epithelium [82], altered
cytoskeletal dynamics, altered morphoregulatory proten expression (adhesion
molecules) [83], enhanced secretion of proteases, cytokines and soluble factors
etc., (iii) redundant physiological processes: proliferation [84, 85], bronchiolar and 
squamous metaplasia, [86-88], apoptosis [89-91] and mesenchymal
transdifferentiation [92, 93]. 
1.5.1. Morphological characteristics of the alveolar epithelium.
The alveolar epithelium is composed of two morphologically distinct cell types, ATI 
and ATII cells. ATI cells are large flattened cells that cover 95% of the lungs’ 
surface area [94], form the barrier to gas exchange and regulate lung liquid 
homeostasis [95, 96]. ATII cells cover the remaining 5% of the lungs’ surface area. 
These are cuboidal cells with rounded nuclei and short microvilli along their apical 
surface. ATII cells have numerous cytoplasmic organelles, including lamellar 
bodies. ATII cells reside in alveolar corners and have many functions [97]. They 
produce, secrete and reuptake surfactant proteins [98-102], transport electrolytes 
from the apical surface into the interstitium [103, 104], synthesize components of 
the basement membrane [105], and contribute to the lung innate immune response 
[106-111]. 
1.5.2. ATII cells: stem cells of the alveolar epithelium.
However, the most remarkable feature of ATII cells is their ability to proliferate and 
differentiate (stem cells characteristics). It is generally accepted that a putative 
subpopulation of ATII cells, hyperplasic ATII cells, give rise to both ATII cells by 
division and ATI cells by transdifferentiation during normal lung growth and repair 
following lung injury [112-115]. The transdifferentiation of ATII cells into ATI cells is 
proposed to progress through an intermediate cell type that exhibits both ATII 
specific and ATI-specific characteristics. Reports show that this transition may be 
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influenced by soluble factors and the extracellular matrix [116] and may be partially
reversible [117-119]. 
The turnover time of ATII cells under normal and pathological conditions is 
significantly different. The turnover time of ATII cells in normal lung is reported to 
elapse between 2-3 weeks [120, 121]. The proliferation kinetics of ATII cells upon 
injury, however, is drastically accelerated. The study of Kauffman SL has 
demonstrated that in urethane-injured adult mice the duration of a complete ATII 
cell cycle is 22 hours [122]. Evans et al. have shown that in NO2-injured rats the 
completeion of ATII cell cycle takes 2-3 days [123].
Bone marrow and nonciliated bronchiolar epithelial cells are also considered stem 
cells of the alveolar epithelium [124, 125]. The plasticity of ATI cells is still 
speculative. Despite of the presumption that ATI cells are terminally differentiated
cells [113]. Reports suggest self repair features of ATI cells [126] and capability to 
transdifferentiate into ATII cells as well [127]. Figure 3 depicts the role of ATII, ATI, 
bone marrow and airway cells in repopulating the lung alveolar epithelium. 
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Figure 3. Progenitor cells of the alveolar epithelium.
ATII cells are pointed out in the above picture as the major proliferative cells of the 
alveolar epithelium, capable of (trans)differentiation. The plasticiity of ATI cells, 
bone marrow and airway epithelial cells are also depicted in this cartoon, adapted 
from [128].
1.5.3. ATII cells and alveolar re-epithealization.
ATII cells proliferation is an essential step in the normal alveolar re-epithealization 
process. Upon injury, the highly vulnerable ATI cells (cell morphology) are primary 
damaged (necrosis/apoptosis). This “drop out” of ATI cells results in denudation of 
the basement membrane. The repopulation of the denuded basement membrane 
comprises the following sequence of events: (i) proliferation of ATII cells; (ii) 
migration of the ATII cells along the surface of the alveolar epithelial basement 
membrane; and (iii) differentiation of ATII cells (hyperplastic subpopulation) into 
ATI cells (Figure 4) 
Figure 4. Representative model of the alveolar epithelial repair process.
a) Upon injury ATI cells show detached flat processes and blebbing as a typical 
feature of denudation, b) In response the activated ATII cells proliferate, migrate 
Introduction
13
across the basement membrane, and differentiate into ATI cells, repopulating the 
alveolar epithelium, adapted from [129].
In IPF, the ability of ATII cells to carry out proliferation, migration and differentiation 
appears seriously compromised [130]. At a comprehensive look the proliferative 
phenotype of AECs in IPF appears to be significantly heterogeneous. Higher rates 
of AEC proliferation have been observed at the broncho-alveolar junction in IPF 
lungs [86]. Multiple studies have reported rapid proliferation of ATII cells following 
injury [131-134]. Conversely, reduced proliferative capacity of ATII cells and/or the 
inability to differentiate into ATI cells have also been reported in IPF [130] and in 
explant lung models of fibrosis [72]. 
1.5.4. Growth factor control of ATII cell proliferation.
ATII cells proliferation appears to be highly regulable. Various growth factors and 
cytokines have been found to influence the proliferative phenotype of ATII cell. 
Some of these regulatory signals have paracrine and autocrine mechanism of 
action. Some exirt effects in a juxtacrine fashion and many are bound to the 
extracellular matrix and potentially available without the need for any local 
production. Growth factors known to stimulate ATII cell proliferation are FGF, 
hepatocyte growth factor (HGF) and epidermal growth factor (EGF). KGF, a 
member of the FGF family, also known as FGF-7, has been shown to be a potent 
mitogen of ATII cells in vivo [135-137]. HGF has been reported to have mitogenic 
and fibrinolytic activities [138]. KGF and HGF are paracrine growth factors. Their 
expression is confined to the mesenchyme, whereas their receptor expression is 
confined to the epithelium [139, 140]. The EGF family of growth factors acts via 
autocrine and juxtacrine pathways. EGF ligands (EGF, TGFα, HB-EGF, etc.) bind 
several subtypes of EGF-R, erbB1 (HER1), erbB2 (HER2), erbB3 and/or erbB4. 
Both the ligands and the receptors are expressed at the cell surface of pulmonary 
epithelial cell [141-143]. Activated EGF receptors induce mitogenic and 
morphogenic cellular responses, which are crucial in the airway and alveoli 
epithelial repair process [144-146].  Conversely, growth factors known to inhibit 
ATII cell proliferation are TGF-β, parathyroid hormone-like growth factor and 
components of the IGF system. TGF-β can completely inhibit the stimulating effect 
of KGF in vitro [147]. Increased expression of IGFBP-2, type-2 IGF receptor and
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IGF-II, is associated with ATII cell growth arrest [148]. 
1.6. Diagnosis and evaluation.
1.6.1. Clinical presentation.
IPF presents insidiously with gradual onset of progressive dyspnoea on exertion 
and a nonproductive cough. The most frequent clinical symptoms are (i) bibasilar, 
end-inspiratory fine crackles on auscultation, predominantly in the lower posterior 
lung zones (typically “dry” and “Velcro” in quality), (ii) abnormal enlargement of the 
fingernail bases (clubbing), (iii) loss of appetite and weight, fatigue, weakness, and 
vague chest pains (iv) blue-colored skin (cyanosis) around the mouth or in the 
fingernails due to low oxygen (advanced disease) [51]. Importantly, the presenting 
clinical symptoms of IPF are non-specific and are often attributed to other diseases. 
Thus, definite diagnosis is frequently delayed with several years from the onset of 
the symptoms. 
1.6.2. Diagnosis.
The accuracy of IPF diagnosis depends on the utilization of the following criteria: (i) 
exclusion of other known causes of IIPs, like drug toxicities, environmental 
exposures and connective tissue disorders with no features to support an 
alternative diagnosis from transbronchial lung biopsy (TLB) or bronchoalveolar 
lavage (BAL) samples, (ii) abnormalities of lung function, which include restricted 
and/or impaired lung gas exchange at rest or exercise or decreased diffuse lung 
capacity for carbon monooxide; and (iii) bibasilar reticular abnormalities (fine 
network of lines) and honeycombing (one or more rows of clustered cysts) and 
architectural distortion on HRCT scans [51] (Figure 5b).
A B
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Figure 5. HRCT abnormalities in IPF. a) HRCT of normal lung, b) HRCT of IPF 
lung, adapted from [149].
1.7. Treatment. 
IPF is a unresolved clinical issue. Treatment options include oxygen therapy and 
pulmonary rehabilitation to improve the breathing of the patients. Lung 
transplantation is a feasible treatment option for selected patients with IPF. 
Convential drug therapies (corticosteroids, IFN-γ1b, N-acetyl cysteine (NAC), 
bosentan, imatinib mesylate etc.) [150] provide only marginal effects. In the light of 
poor prognosis and lack of available drug therapy alternative therapeutic strategies 
should be persued. New treatment approaches for IPF patients should include 
agents that inhibit alveolar epithelial injury or enhance alveolar epithelial repair, 
anti-inflammatory and anti-oxidant approaches, agents that inhibit fibroblast 
proliferation or induce fibroblast apoptosis.
1.7.1. Phosphodiesterase (PDE) inhibitors.
In the recent years it had become readily apperant that PDE inhibitors might serve 
as effective and specific therapeutic agents. Of interest, effective PDE inhibitor 
therapies have been demonstrated for a variety of proliferative pulmonary 
disorders: pulmonary arterial hypertension [151-153], cancer [154-156], asthma 
and chronic obstructive pulmonary disease [157, 158]. Most importantly, a 
particular PDE inhibitor (sildenefil) had shown beneficial effects in experimental 
models of pulmonary fibrosis and IPF secondary to PAH [159-161]. Hence forth, 
PDEs and PDE inhibitor strategy in IPF of specific need to be investigated.
2. PDEs.
PDEs form a large superfamily of enzymes that metabolize the ubiquitious second 
messenger molecules cyclic guanosine monophosphate (cGMP) and cyclic 
adenosine monophosphate (cAMP) to their respective inactive 5' monophosphates 
GMP and AMP (Figure 6). To date, 11 families of PDEs with varying selectivities 
for cGMP and cAMP have been identified in mammalian tissues. Each of the PDE 
families contain multiple isoforms, expressed either as products of different genes 
or as products of the same gene through alternative promoter initiation and/or 
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alternative mRNA splicing. Thus, the mammalian PDE superfamily (class I PDEs) 
is composed of more than 50 isoenzyme variants [162-166]. Notably, the individual 
PDE families have unique tissue, cellular, and sometime subcellular distributions 
[166], thus contributing to the compartmentalization of the cyclic nucleotide 
signaling. The unique characteristics of each PDE family and their pharmacological 
inhibitory profiles are summarized in Table II (appendix). 
Figure 6. Chemical basis of PDE enzymatic activity.
The cartoon shows PDEs as enzymes that hydrolyze the 3’ cyclic phosphate bond 
in the ribose ring of cAMP and cGMP, adapted from [167].
2.1. Cyclic nucleotide specificity.
Of the 11 PDE families, 3 families specifically hydrolyze cGMP (PDE5, PDE6 and 
PDE9), 3 families specifically hydrolyze cAMP (PDE4, PDE7 and PDE8) and 5 
families hydrolyze both cyclic nucleotides with varying efficiency (PDE1, PDE2, 
PDE3, PDE10 and PDE11). The substrate specificity of the PDE enzymes is 
defined by the hydrogen-bonding network properties of their catalytic domain. In 
the catalytic pocket of PDEs 5, 6 and 9 invarient glutamine is fixed by neighbouring 
residues into a position that favours cGMP binding. Conversly, for PDEs 4, 7 and 8 
this gutamine is constrained by neighbouring residues into a position that favours 
cAMP binding. Consistently, for bisubstrate specific PDEs the glutamine is able to 
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rotate freely, thus allowing hydrogen-bonding network formation for both cyclic 
nucleotide molecules [168]. 
2.2. cGMP. 
cGMP controls a diverse array of physiological processes, including vascular 
smooth muscle relaxation, natriuresis, platelet function, neutrophil adhesion, sperm 
motility, neuronal signaling, and sensory transduction. cGMP is a common 
regulator of ion channel conductance, glycogenolysis, and cellular apoptosis [169]. 
cGMP play a key role in controlling epithelial cell functions such as ciliary motility 
and cytokine production [170-172]. Moreover, cGMP hemodynamics are of great 
essentiality for the phototransduction responses in the mammalian eye [173]. 
cGMP exerts its biological responses via activation of cGMP-dependent protein 
kinases, cyclic nucleotide-gated channels and cGMP binding proteins. Cytoplasmic 
levels of cGMP may be modulated non enzymatically by sequestering proteins 
[174], and/or by transport mechanisms that cause cGMP efflux from the cells [175]. 
However, the amplitude and the duration of cGMP signaling are mainly regulated 
enzymatically by the balanced activities of guanylyl cyclases (GCs) and the 
competing action of cGMP PDEs.
GCs are a family of enzymes that catalyzes the conversion of guanosine 
triphosphate (GTP) to cGMP. GCs exist in two forms: a soluble form and a 
membrane-bound (particulate) form [176-178]. The soluble GC (sGC) is a heme-
containing heterodimer, consisting of  and β subunits, which make up the active 
enzyme. The sGC is activated upon NO and NO donors binding. The particulate
GC is a plasma membrane receptor for the natriuretic peptides: BNP (B-type
natriuretic peptide), ANP (atrial natriuretic peptide), CNP (C-type natriuretic. 
peptide) and related hormones [176, 178] (Figure 7). 
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Figure 7. cGMP metabolism.
The metabolism of cGMP is controlled by the synthetic enzymes: sGC and 
particulate GC and the hydrolytic enzymes: PDEs. cGMP elicits diverse biological 
reponses via activation of PKG, adapted from [179]. NO nitric oxide, sGC soluble 
guanylyl cyclase, BNP B-type natriuretic peptide, ANP atrial natriuretic peptide, 
CNP C-type natriuretic. peptide, GS guanylyl cyclase, GTP guanosine triphosphate, 
cGMP cyclic guanosine monophosphate, PKG cGMP-dependent protein kinase G, 
PDE phosphodiesterase. Author’s slide.
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2.3. cGMP PDEs.
cGMP PDEs are categorized in three major subgroups: cGMP-stimulated cyclic 
nucleotide PDEs [180], photoreceptor cGMP-specific PDEs [181, 182], and cGMP-
binding cGMP specific PDEs described in lung and platelets [183, 184].
The cGMP degrading PDE enzymes are notable for the presence of tandem 
GAFa/GAFb motifs in their regulatory region. The GAF acronym is derived from the 
names of the first three classes of proteins recognized to contain this domain: 
mammalian cGMP-binding PDEs, Anabaena adenylyl cyclases, and Escherichia 
coli FhlA [185]. GAF domains in PDEs provide for dimerization, cyclic nucleotide 
binding and allosteric regulation [186, 187]. Three of the five GAF domain-
containing PDEs (PDE2, PDE5, and PDE6) serve as feedback regulation sides of 
cyclic nucleotide signaling by virtue of cAMP/cGMP binding to one of the tandem 
GAF domains. The GAF domains in PDE10 and PDE11 are poorly characterized. 
There is no clear report on allosteric regulation of PDE10 and PDE11 by cGMP 
[188-190]. 
cAMP/cGMP binding to the regulatory GAF domains in PDE2, PDE5 and PDE6 
have differential effect on their enzymatic activities. Binding of cGMP to the GAFb 
domain of PDE2 is responsible for a direct allosteric stimulation (approximately 10-
fold) of enzymatic activity [191-194]. Additionally, binding of cAMP to the GAFb 
domain of PDE2 also stimulates enzymatic activity [187, 192]. For PDE5, cGMP
binding to the GAFa domain increases PDE5 catalytic activity directly [195, 196]. 
Moreover, cGMP binding to the GAFa domain of PDE5 induces conformational 
changes that exposes a serine residue (Ser102 in human PDE5 enzyme and 
Ser92 in bovine PDE5 enzyme) for phosphorylation by either PKG or the catalytic 
subunit of protein kinase A (PKA), which in turn activates both catalytic and 
allosteric cGMP-binding activities of PDE5 [197]. Unlike PDE2 and PDE5, cGMP 
occupancy of the GAFa domain of PDE6 reduces the basal activity of the enzyme. 
An effect related to enhanced affinity of the inhibitory PDE6G/H subunit for the 
catalytic dimer of the PDE6 enzymes [198, 199]. Reciprocally, binding of the 
inhibitory PDE6G/H subunit to the catalytic core of the enzyme enhances cGMP 
binding to the PDE6 GAFa domain [200, 201]. The arrangement of the catalytic 
and GAF domains in PDE2, PDE5, PDE6, PDE10 and PDE11 is given in Figure 8.
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Figure 8. Schematic representation of catalytic and GAF domains 
arrangement in cGMP PDEs. 
GAF domains with delineated regulatory properties are represented with solid line. 
GAF domains with currently unknown regulatory properties are represented with 
dotted line, adapted from [166, 202]. Author’s slide.
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2.4. cGMP PDEs in the lung.
Of the major cGMP degrading PDEs (PDE5, 6 and 9), PDE5 is considered the 
most abundant cGMP metabolizing enzyme in the lung [203-205]. PDE5 activity is 
ascribed mainly to pulmonary smooth muscle cells [206, 207] and is thought to limit 
the vasodilator and antiproliferative effects of cGMP-mediated vasoactive factors, 
such as NO and the natriuretic peptides on the pulmonary vasculature. Besides 
minor PDE5 activity is reported in bronchial epithelial cells [208] with speculated 
role in inflammation and remodeling processes [209]. 
Lung expression of PDE9 is reported as well [210]. The biological role of PDE9A is 
currently not well characterized. The high affinity of PDE9A for cGMP, 20 folds 
higher than that of PDE5, suggests its critical importance in cGMP-driven 
processes [183]. 
2.5. PDE6.
Until now, there are no reports regarding lung expression of PDE6. This enzyme is 
thought to be primary localized in the rod and cone photoreceptive cells of the 
mammalian retina [211]. The rod PDE6 enzyme is composed of two catalytic 
subunits PDE6 and PDE6, encoded by PDE6A and PDE6B genes respectively, 
two identical inhibitory subunits PDE6, encoded by PDE6G [212, 213] and one 
regulatory subunit PDE6, encoded by the PDE6D gene [214]. The cone PDE6 
enzyme represents two identical catalytic subunits PDE6’, encoded by PDE6C 
gene and two identical cone-specific inhibitory subunits PDE6’, encoded by 
PDE6H gene [182] (Figure 9). 
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Figure 9. Schematic subunit composition and structure of rod and cone 
PDE6 enzymes.
The catalytic core of rod PDE6 enzyme is represented by PDE6A and PDE6B 
subunits. The catalytic core of cone PDE6 is represented by two identical PDE6C 
subunits. The regulatory domains of both rod and cone PDE6 are represented by 
tandem GAF domains (GAFa and GAFb). Both enzymes contain regions at their 
catalytic and GAF domains that interact with the respective inhibitory subunit 
PDE6G and PDE6H. The PDE6D subunit, which is unique to the rod PDE6 
enzyme, is also shown in the picture. PDE6D interacts with the catalytic core 
(PDE6A and PDE6B) of the rod PDE6 enzyme and defines enzyme solubilization 
from the plasma membrane, adapted from [211, 215]. Author’s slide.
2.5.1. Phototransduction.
PDE6 is known for its pivotal role in the phototransduction process [216-218]. It is 
considered the primary regulator of cytoplasmic cGMP concentration in the eye. In 
dark, PDE6 exists in an inactive form. The relatively high cGMP levels (several µM) 
permit a fraction of the cGMP-gated ion channels in the plasma membrane to 
remain open, allowing a current to circulate through the photoreceptor cells. 
Photoexcitation of a visual pigmen (rhodopsin in rod photoreceptive cells and 
iodopsin in cone photoreceptive cells) activates a photoreceptor G-protein, 
transducin. The activated  subunit of transducin interacts with the PDE6 
holoenzyme, causing its activation by removal of the inhibitory PDE6G/H subunit. 
The activated PDE rapidly hydrolyzes cGMP. Fast depletion of cGMP in the outher 
segments of the photoreceptors results in a closure of cGMP-gated cation 
channels and a drastic Na+ and Ca2+ depletion in the photoreceptive cells 
(blockage of Na+ and Ca2+ entry and continuous work of Na+/Ca2+-K+ exchangers). 
The ensuing hyperpolarization initiates the photoresponse of the photoreceptor 
neuron. Low intracellular Ca2+  levels promote activation of GC by gyanylate 
cyclase activating protein (GCAP), boosting up the cGMP leveles and closing up 
the circle of photoreceptors activation/deactivation [215, 219] (Figure 10).
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Figure 10. Vertabrate visual phototransduction cascade.
Shown in the picture is the visual excitation pathway in rod photoreceptors. 
Photoactivation of rhodopsin results in a GDP to GTP exchange at the  subunit of 
transducin. The activated  subunit of transducin (T-GTP) de-represses the 
blockade of the inhibitory PDE6G subunit from the catalytic core of the rod PDE6 
enzyme, making the ezyme active and capable of degrading cGMP. The drop in 
cGMP levels in the outher segment causes dissociation of cGMP from the cGMP-
gated ion channels in the plasma membrane, causing their closure. The reduced 
entry of cations (Na+ and Ca2+) in the outher segment causes membrane 
hyperpolarization and ultimate generation of the receptor potential at the 
photoreceptor synapse. Reactions involved in the recovery of the photoresponse 
(elevation of cGMP levels through activation of GCAP) are also schemed above, 
adapted from [211, 215]. R rhodopsin, T transducin, PDE rod phosphodiesterase 6,
GCAP gyanylate cyclase activating protein, GC guanylyl cyclase. Author’s slide.
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Recently, an interaction between the PDE6 and Wnt/Ras signaling cascades has 
been reported in non-retinal tissues. Wang H et al. have postulated that the 
atypical Wnt/Ca2+/cGMP pathway implicated in development involves PDE6 [220]. 
Nancy et al. have demonstrated that the PDE6D subunit regulates the membrane 
association of Ras and Rap GTPases [221]. This suggests functionality of PDE6 in 
non-retinal tissues and brings up the question of PDE6 expression in human lung 
in general, along with a plausible role for PDE6 in IPF.
Analysis of PDE6 functional assembly and activity in retinal and non-retinal tissues, 
however, is hampered by the unique characteristics of this enzyme: (i) functional 
assembly of the PDE6 complex requires at a minimum all subunits, (ii) enzyme 
activity is determined by various posttranslational modifications: N-terminal 
acetylation, C-terminal isoprenylation and carboxylmethylation, (iii) functional PDE6 
expression pre-requests additional chaperon proteins [222]. Thus, we opted to 
characterize a complex independent function of the specific PDE6D subunit.
2.5.2. The PDE6D subunit.
In the context of phototransduction the PDE6D subunit defines the solubilization of 
the PDE6 enzyme from the plasma membrane and consequently the uncoupling 
from its effector transducin via interaction with the isoprenylated C-termini β 
catalytic core of the enzyme [223]. However, the role of PDE6D extends beyond 
retinal tissue and the phototransduction cascade. This highly conserved protein 
sequence [224] has been detected in a variety of non-retinal tissues, including,
heart, placenta, lung, brain, skeletal muscles and liver [223, 225]. A substantial 
body of information has been reported on the individual functional capacity for
PDE6D apart from its role in the rod PDE6 enzyme complex [226]. PDE6D is 
reported to regulate the membrane association of Ras and Rap GTPases in a 
manner similar to guanine nucleotide dissociation inhibitor (GDI), but independent 
of the nucleotide-bound state (GDP/ GTP) of the small GTPase [221]. PDE6D has 
also been proposed to play a role in vesicular transport as an effector for, or via 
forming a complex with, Arl1, Arl2 and Arl3 [227, 228] and Rab13 [229]. 
Furthermore, PDE6D has been shown to be instrumental for the internalization and 
recycling of the human prostacyclin receptors [230]. In the present study, we asked 
whether PDE6D modulates the proliferation rate of AECs and specifically what are 
the signaling mechanisms accounting for PDE6D effects on AECs proliferation.
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CHAPTER 2: AIMS
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II. Aims of the study. 
IPF is a progressive interstitial lung disorder associated with high morbidity and 
mortality. At present there is no demonstrably effective therapy for blocking or 
reversing the progression of the disease. Current evidences suggest that a 
possible therapeutic approach may include the use of sildenafil, a cGMP PDE5 
inhibitor [159, 231]. However, the plausible contribution of other cGMP PDE 
isoforms to the pathogenesis of IPF has received relatively little attention. Thus, the 
present study was designed to analyze the expression profile of cGMP PDEs in 
lung tissues from donors and IPF patients. And consequently, focused on the 
characterization of PDE6, a previously unexplored cGMP degrading enzyme in the 
context of human pulmonary system and pulmonary disorders. In that respect the 
study design included the following aspects:
1. to characterize mRNA expression profile of cGMP PDEs in lung tissues from IPF 
patients as compared to donor lung tissues.
2. to evaluate PDE6 mRNA expression in human lung and the corresponding 
mRNA alterations in lung tissues from IPF patients. 
3. to evaluate PDE6 protein expression in human lung and the corresponding 
protein alterations in lung tissues from IPF patients. 
4. to assess the cellular and subcellular distribution of PDE6 subunits in lung 
tissues from donors and IPF patients.
5. to explore functional capacity of the specific PDE6D subunit in terms of AEC
proliferation.
6. to delineate signaling pathways accounting for PDE6D effects on AEC
proliferation.
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CHAPTER 3: MATERIALS AND
METHODS
“Though this be madness, yet there is method in it”
William Shakespeare, 1564 - 1616
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III. Materials and Methods.
3.1. Materials.
3.1.1. Instruments, consumables, chemicals and enzymes.
Instruments, consumables, chemicals and general reagents commonly used in the 
experimental protocols of this thesis are listed below:
Instrument Company name
Autoclave Tuttnauer systec
Beta counter Canberra Packard
BioDoc Analyzer Biometra
Cell culture incubator Heraeus
Cell culture microscope Hund Wetzlar
counter plate reader (Type LP 400) TECAN
Culture Hood (HB2448) Heraeus
Developing machine Curix 60 AGFA
Electrophoresis apparatus system Biometra, Bio-Rad
Film cassette Amersham Biosciences
Fine scale (Mettler PM460) Scaltec
Freezer,  -20 C Bosch
Freezer,  -80 C Sanyo
Heat block (TM 130-6) HCL
Light microscope Leica
Liquid nitrogen tank Arpege 40
Lysis&Homogenization automated equipment PeqLab
Magnetic stirrer Bibby Stuard
Mega centrifuge (J-TB-024D) Beckman
Microwave oven Lotus
Mikrofuge Hettlich
Mini spin centrifuge Biofuge fresco, Heraeus
NonoDrop Spectophotometer PeqLab
PCR-termocycler Biometra
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pH meter InoLab
Pipettes: P10, P20, P100, P200, P1000 Eppendorf
Pipetus Hirsschmann Laborgerate
SDS-PAGE gel system Biometra, Bio-Rad
Shaker (WT 17) Biometra
Spectrophotometer Eppendorf
Temperature chamber Binder
UV-Transilluminator Biometra
Vortex Scientific Industries
Water bath Medingen
Water filter unit Millipore
Western-Blot chamber Bio-Rad
Consumable Company name
Barrier food wrap Saran
Blotting papper (3 mm) Whatman
Cover slips RL
Cryogenic vials Corning
Eppendorf tubes, (1.5ml, 2ml) Bio-Rad
Falcon centrifuge tubes (15 ml, 50ml) Falcon
Hyper-sensitive X ray film Amersham
Low-sensitive X ray film AGFA
Nitrocellulose membrane (0.2 µm) Bio-Rad
Scintillation vials SGE
Tissue culture dishes (30 mm, 60 mm, 100 mm) Cell Star
Tissue culture flasks (75 cm2) Cell Star
Tissue culture suspension plates (6, 12, 24, 48 
wells)
Cell Star
Chemical or Enzyme Company name
3-4,5-dimethylthiazol-2,5 diphenyl tetrabromide
(MTT)
Sigma
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Agarose, for routine use Sigma
Ammonium persulfate (APS) Sigma
Aqua B Braun B Braun
β-mercaptoethanol Sigma
Bovine serum albumin  (BSA) Serva
Bradford reagent Biorad
Bromophenol blue Merck
Calcium Chloride (CaCl2) Sigma
Chloroform, minimum 99% Sigma
Citrate buffer 20x Zymed lab
Complete Mini, EDTA-free protease inhibitor
cocktail
Roche Diagnostics GmbH
DEPC-treated  water Fermentas
Dimethylsulfoxid (DMSO) Sigma
Di-Sodium hydrogen phosphate anhydrous
(Na2HPO4)
Merck
Disodium Phosphate (Na2HPO4) Sigma
Ethanol (absolute) Roth
Ethidium bromide (EtBr), 0.025% Roth
Ethylene glycol-bis-(2-aminoethyl)-N,N,N', N'-
tetraacetic acid (EGTA)
Serva
Ethylenedioxy-diethylene-dinitrilo-tetraacetic acid 
(EDTA)
Fluka
GeneRuler 100bp DNA Ladder (1 kb) Fermentas
GeneRuler DNA Ladder Mix (10 kb) Fermentas
Glacial acetic acid, minimum 99% Sigma
Glucose Sigma
Glycerol Sigma
Glycine Sigma
Hydrochloric acid fuming, 37% Merck
Hydrochloride (HCl) Roth
Iso-propyl alcohol (isopropanol) Roth
Magnesium chloride (MgCl2) Merck
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Magnesium sulfate (MgSO4) Sigma
Methanol (MeOH) Fluka
Methyl-[3H]-Thymidine, 250Ci Amersham 
N-2-Hydroxyethylpiperazine N’-2-Ethinesulfonic
Acid (HEPES), minimum 99.5%
Sigma
Nonidet-P40 (NP-40) Substitute Fluka
Pfu DNA polymerase Promega
Phenymethanesulfonyl fluoride (PMSF) (0.1M) Fluka
Potassium chloride (KCl) Roth
Potassium dihydrogen phosphate (KH2PO4) Roth
Rainbow marker Amersham
Scintillation liquid (Rotiszint eco plus) Roth
Sodium chloride (NaCl) Sigma Aldrich
Sodium dodecyl sulfate (SDS) Merck
Sodium hydrogen carbonate (NaHCO3) Fluka
Sodium hydroxide (NaOH) Merck
Sodium orthovanadate (Na3VO4) Sigma
Taq Polymerase Promega
TEMED (N,N,N’,N’-Tetramethyl-ethylene diamine) Serva
Trichloroacetic acid (TCA), minimum 99% Sigma Aldrich
Triton X-100 (t-Octylphenoxypolyethoxyethanol) Sigma
Trizma base, minimum 99.9% titrationTris HCl Sigma
Trizol reagent Invitrogen
Tween 20 Sigma Aldrich
Xylol Merck
3.1.2. Cloning reagents.
 Reagent Company name
Ampicilin Invitrogen
dATP Promega
IPTG Promega
LB agar Invitrogen
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LB base Invitrogen
Soc medium Sigma
X-gal Promega
LB agar medium 
(50 g/ml ampicillin)
25 g LB broth dissolved in 1 l of double distilled water, 
sterile autoclaved (121°C, 15 min),  1ml of 50 mg/ml 
ampicillin stock solution addeded when the medium 
cooled down
LB agar plates 
1.5% agar
50 g/ml ampicillin
100 M IPTG
50 g/ml X-gal
32 mg LB agar dissolved in 1 l of distilled water, sterile 
autoclaved (121°C, 15 min), 1 ml of 50 mg/ml ampicillin, 
1 ml of 100 mM IPTG, 1 ml of 50 mg/ml X-gal addeded 
when the medium cooled down, LB agar poored into 
petri dishes and let harden at room temperature
E. coli strain utilized in the cloning procedure: 
JM 109 competent cells (>108 cfu/ g) Promega
3.1.3. Cell culture materials.
Cell culture and transfection reagents Company name
DMSO Sigma
DMEM F12 Invitrogen
FBS PAA Laboratories 
L-glutamine PAN
Lipofectamine-2000 Invitrogen
MEM NEAA (100x) Gibco
MEM vitamins Gibco
Opti MEM-I +glutaMax-I Gibco
PBS PAN
Penicillin-streptomycin solution (100x) PAA Laboratories 
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Trypsin-EDTA (10x) PAN
Complete DMEM F12 
medium
10% FBS, 1% MEM vitamin solution, 2 mM glutamate 
1% MEM non-essential amino acids
Cell line utilized in the cell culture experiments:
A549 (human alveoar epithelial cells) American Type Culture 
Collection (Manassas, VA)
3.1.4. Antibodies, blocking peptides and siRNA targeting sequences.
Antibody Company name
anti-PDE6A rabbit polyclonal IgG FabGennix, Abcam
anti-PDE6B rabbit polyclonal IgG FabGennix, Proteintech 
anti-PDE6D rabbit polyclonal IgG FabGennix, Abcam
anti-PDE6G rabbit polyclonal IgG FabGennix, Abcam
anti-total AKT rabbit polyclonal IgG Santa Cruz
anti-phospho AKT (Ser 473) rabbit polyclonal IgG Santa Cruz
anti-total ERK rabbit polyclonal IgG Santa Cruz
anti-phospho ERK (Tyr 204) rabbit polyclonal IgG Santa Cruz
anti-GAPDH mouse IgG Novus Biologicals
anti--actin mouse IgG Abcam
HRP conjugated rabbit anti-mouse IgG Sigma Aldrich
HRP conjugated goat anti-rabbit IgG Pierce
Immunizing peptide Company name
anti-PDE6A immunizing peptide
M(1)GEVTAEEVEKFLDSN(16)C
Abcam
anti-PDE6B immunizing peptide
H(20)QYFG(K/R)KLSPENVAGAC(36)
Abcam
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PDE6D siRNA target sequence
Sense         5’-GGC-AGU-GUC-UCG-AGA-ACU-U-3’
Antisense  5’-AAG-UUC-UCG-AGA-CAC-UGC-C-3
3.1.5. Kits.
Kit Company name
AEC staining kit Zymed Laborotories
ECL chemiluminescence kit Amersham
Endofree plasmid maxi kit Qiagen
ECL solution kit Amersham
Gel extraction kit Qiagen
Improm II Reverse Transcription system Promega
Miniprep kit Qiagen
pcDNA3.1 directional TOPO cloning kit Invitrogen
pGEM-T easy vector system II Promega
3.1.6. Buffers and solutions.
Buffer or Solution (1 l) Composition
Blocking solution 5 % skim milk powder in wash buffer
Buffer EB (elution buffer) 10 mM Tris-Cl, pH 8.5 
Buffer ER (endotoxins removing 
buffer)
Proprietary formulation (Qiagen)
Buffer N3 (neutrallization buffer) Proprietary formulation (Qiagen)
Buffer P1 (resuspension buffer) 50 mM Tris-Cl, pH 8.0, 10 mM EDTA
Buffer P2 (lysis buffer) 200 mM NaOH, 1% SDS
Buffer P3 (neutrallization buffer) 3.0 M Potassium acetate, pH 5.5
Buffer PB (binding buffer) Proprietary formulation (Qiagen)
Buffer PE (wash buffer) Proprietary formulation (Qiagen)
Buffer QBT (equilibration buffer) 750 mM NaCl, 50 mM MOPS, pH 7.0, 15% 
Isopropanol, 0.15% Triton
Buffer QC (wash buffer) 1.0 M NaCl, 50 mM MOPS, pH 7.0, 15% 
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Iopropanol
Buffer QG (solubilization and 
binding buffer)
Contains guanidine isothiocyanate, pH 7.5
Buffer QN (elution buffer) 1.6 M Nacl, 50 mM MOPS, pH 7.0, 15% 
Isopropanol
Buffer TE (solubilization buffer) 10 mM Tris, pH 8.0, 1 mM EDTA
Citrate buffer (20x) Zymed Laboratories
DNA loading dye (6x) 40% glycerol, 50 mM EDTA, 0.03% 
bromophenol blue, 0.4% orange G, 0.03% 
xylene cyanol
Freeze medium 70% complete DMEM-F12, 20% FBS, 10% 
DMSO
Gel loading buffer (6x) 40% glycerol, 50 mM EDTA, 0.03% 
bromophenol blue, 0.03% xylene cyanol
HBSS (1x) (Gibco) 0.137 M NaCl, 5.4 mM KCl, 0.25 mM 
Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 
1.0 mM MgSO4, 4.2 mM NaHCO3
Hypotonic lysis buffer (1x) 10 mM HEPES, 10 mM NaCl, 1 mM 
KH2PO4, 5 mM NaHCO3, 1 mM CaCl2, 0.5 
mM MgCl2, 5 mM EDTA pH 7.5, 1 mM
PMSF and 1x complete mini protease 
inhibitor cocktail
Laemmli buffer (5x) 10% SDS, 50% Glycerol, 25%  -
mercaptoethanol, 300 mM Tris-Cl pH 6.8.
0,04% bromophenol blue
PBS (1x) 1.3 mM KCl, 0.5 mM KH2PO4, 135 mM 
NaCl, 3.2 mM Na2HPO4
Protein lysis buffer (1x) 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 
20 mM Tris-HCl pH 7.6, 5 mM EDTA, 1 mM
EGTA, 1 mM PMSF, 1x Roche complete 
mini protease inhibitor cocktail
Running buffer (1x) 25 mM Tris, 192 mM glycine, 0.1 % SDS 
Stripping buffer 12.5 ml 0.5 M Tris-HCl (pH 6.8), 0.7 ml ß-
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mercaptoethanol, 20 ml 10% SDS
TAE (50x) 2 M Tris, 5.5% acetic acid, 1.25 M EDTA (pH 
8.8)
TBS (20x) 25 mM Tris, 2.75 mM NaCl, adjust to pH 8.0
Transfer buffer (1x) 20 mM Tris, 40 mM glycine, 20% methanol
Wash buffer 1/5 volume of 20x TBS, 0.1% Tween-20
SDS-PAGE stacking gel
(4%) (ml)
0.89 ml ddH2O, 0.375 ml 0.5 M Tris HCl, pH 6.8, 0.015
ml 10% SDS, 0.2 ml 30% PAA, 0.015 ml 10% APS, 
0.0015 ml TEMED
SDS-PAGE resolving 
gel (10%) (ml)
1.78 ml ddH2O, 1.13 ml 1.5 M Tris HCl, pH 8.8, 0.045 
ml 10% SDS, 1.5 ml 30% polyacrylamide (PAA), 0.045
ml  10% APS, 0.002 ml TEMED
3.2. Methods.
3.2.1. Human lung tissue.
Lung tissue biopsies were obtained from 10 IPF patients with histological UIP pattern 
(4 females, 6 males, mean age = 56  4). Detailed patients characteristics are listed in 
Table V (appendix). The study protocol for tissue donation was approved by the Ethik-
Kommission am Fachbereich Humanmedizin der Justus-Liebig-Universitaet Giessen of 
the University Hospital Giessen (Germany) in accordance with national law and with 
Good Clinical Practice/International Conference on Harmonisation guidelines. Informed 
consent was obtained from each individual patient or the patient’s next of kin. 
3.2.2. RNA isolation.
Total RNA was isolated from exponentially growing cells and animal tissues using 
TRIzol reagent. Whole cell pellets were resuspended and animal tissues homogenised 
using Lysis&Homogenization automated equipment (PeqLab).
Briefly, 100 mg of lung tissues were homogenized in 1.0 ml TRIzol reagent, incubated 
for 10 min and spinned to get rid from the debris. The supernatant was mixed with 0.2 
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ml of chloroform. Samples were shaken vigorously by hand for 15 sec and incubated 
at room temperature for 2-3 min. Following centrifugation (12,000 x g, 15 min, 4°C), 
the aqueous phase was transferred into a fresh tube and mixed with 0.2 ml of 
isopropanol. After a further 10 min incubation the samples were centrifuged (12,000 x 
g, 10 min, 4°C), the supernatant removed and the RNA pellet washed in 75% RNA-
graded ethanol. RNA pellets were resuspended in DEPC-treated water and stored at -
70°C. RNA concentration and purity were measured spectroscopically (Nanodrop) by 
its absorbance at 260 nm and 280 nm. RNA purity was considered good when the 
A260/A280 ratio was between 1.7 and 2.1. For the estimation of RNA concentration the 
below formula was employed:
RNA concentration=A260 x dlution factor x 40 (g/mlRNA)
3.2.3. cDNA synthesis. 
Isolated total RNA was used to synthesize complementary DNA (cDNA) using Improm
II reverse transcription system (Promega, Germany). The PCR cycles were performed 
in T 3000 Thermocycler (Biometra). Briefly, 5 µg of total RNA was combined with 0.5 
µg of Oligo(dT)15 in nuclease-free water for a final volume of 5 µl per RT reaction.This 
mixture was thermally denatured at 70°C for 5 min and rapidly chilled on ice. After a 
short spin, the reverse transcription reaction mix (see below) was added and incubated 
at 25°C for 5 min followed by incubation at 42°C for 1 h. Subsequently, the reaction 
mix was incubated at 70°C for 15 min for thermal inactivation of the reverse 
transcriptase. After synthesis, cDNA samples were either used immediately for PCR, 
or stored at -20°C.
Reverse Transcriptase reaction mix
Reagent Reaction volume (µl)
ImProm-II Reaction buffer (5x) 4.0 
MgCl2 (25 mM )* 2.0 
dNTP mix (10 mM) 1.0 
RNasin® Ribonuclease Inhibitor 1.0 
Nuclease-Free Water X 
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ImProm-II Reverse Transcriptase 1.0 
Final volume 15.0 
*optimal Mg2+ concentration range is 1.5-8.0 mM
3.2.4. PCR.
To check for the presence of the gene of interest either in the animal tissue or cells, 
PCR was performed. PCR signal was amplified using the gene specific primers 
designed from the sequence available in the Genbank. For standard PCR, 20-23 bp 
long primers were designed, AT and GC content was checked and the difference in the 
melting temperature (Tm) between the forward and reverse primers was kept not more 
then 2-4ºC. The primer sequence was checked using the NCBI BLAST search for 
probable similarity with unrelated genes. PCR reaction was done in 0.2 ml thin wall 
tubes in T 3000 Thermocycler (Biometra). PCR for cDNA without reverse transcriptase 
was also done to check for genomic DNA contamination. Each primer pair was 
checked with several annealing temperatures depending on the Tm of the primer pair 
to get a single and specific PCR band. Gene specific primer sequences and RT-PCR 
conditions are given in Table III (appendix).
3.2.5. RT-PCR.
Semi quantitative RT-PCR was performed on cDNA samples by use of Taq DNA 
polymerase. The reaction mixture included:
PCR reaction mix
Reagent Reaction volume (l) Final concentration
10x buffer 2.5 1x
MgCl2 (25 mM) 1.5 1.5 mM
10 pmole/ l FORWARD primer 1.25 0.5 M
10 pmole/ l FORWARD primer 1.25 0.5 M
dNTP mix (10 mM) 0.5 0.2 mM
5 U/ l Taq DNA polymerase 0.1 0.5 U/ 25 l
ddH2O2 X
cDNA template X 0.1-0.2 g/ 25 l
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Final volume 25.0
The tubes were flicked to mix and microfuged briefly before taking to the PCR machine. 
The thermal cycler’s program was as follows:
Initial denaturation 94oC 5 min
Denaturation 94oC 45 s
Annealing variable 45 s
Extension 72oC 1 min
Final extension 72oC 10 min
Cycles 30-35
3.2.6. Agarose gel electrophoresis and PCR product purification.
PCR reactions were analyzed on appropriate % agarose gels in 1X TAE buffer, 
containing 0.5 μg/ml ethidium bromide. Samples were diluted in 6:1 ratio with DNA 
loading buffer (6x). Gel was run in 1X TAE buffer for 60 min at 80 V. Depending on the 
fragment size either GeneRuler 100 bp DNA Ladder (1 kb) or GeneRuler DNA Ladder 
Mix (10 kb) (Fermentas) were used. DNA bands were visualised under UV-
Transilluminator of Biometra system. For semi-quantitative analysis of the PCR 
product, 10 – 20 μl of each reaction was used for electrophoresis. PCR signals were 
quantified in arbitary units (A.U) from optical density x band area. PCR signals were 
normalized to the GAPDH signal of the corresponding RT product to get a semi-
quantitative estimate of the gene expression. The PCR product was purified with the 
QIAGEN gel extraction kit. Briefly, samples were loaded onto the gel. After gel run the 
corresponding bands were excised and placed in 1.5 ml eppendorf tubes. Then add 
300 μl of buffer QG for every 100 mg of gel. Incubate the gel slices in buffer QG at 
50°C for minimum 15 min. Then add 100 μl of isopropanol and placed in a QIAquick 
column. Centrifuge for 1 min at maximum speed. Then add 500 μl of buffer QG to the
column and centrifuge again. After add 700 μl of buffer PE (containing ethanol) to the 
column and incubated for 5 min at room temperature. After centrifugation, place the 
column into a fresh 1.5 ml recovery tube and added 30 μl of prewarmed buffer EB 
directly to the center of the column. Incubated for 10 min at room temperature and then 
centrifuged for 2 min at 12,000 rpm. Discard the column and store the DNA at -20°C. 
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Further identities of transcripts were confirmed by DNA sequencing (AGOWA, 
Germany), where necessary.
3.2.7. Western blotting.
Total protein was isolated from exponentially growing cells and animal tissues using 1x
protein lysis buffer. Whole cell pellets were resuspended and animal tissues 
homogenised using Lysis&Homogenization automated equipment (PeqLab). Briefly, 
lysates were centrifuged at 12,000 x g for 30 min at 4°C. Subcellular fractination was 
carried out in hypotonic lysis buffer at 110,000 x g for 1 h at 4°C (ultracentrifugation) to 
separate cytosolic proteins (supernatant) and crude plasma membrane proteins 
(pellet). Protein concentration was estimated using Bradford assay with a bovine 
serum albumin (BSA) standard. Equal amounts of protein in equal volumes of 1x 
protein lysis buffer were diluted in 5:1 ratio with 5 x Laemmli buffer and boiled for 5 min 
at 95°C. Subsequently, 20-50 μg proteins were run on appropriate % of SDS-
polyacrylamide (SDS-PAGE) gel at a constant voltage of 130 V for 1-1.5 h in 1x 
running buffer. Upon completion of electrophoresis, the gel was carefully removed from 
glass plates. Gels were blotted onto nitrocellulose membrane using a wet tank transfer 
technique. Firstly, gel, whatman filter paper and nitrocellulose membrane were pre-
soak in 1x transfer buffer for 5 min. The transfer sandwich (from cathode to anode (-
/+)) was assembled as followes: two layers of whatman filter paper, gel, nitrocellulose 
membrane and two layers of whatman paper. Special attention was paid to eliminate 
all air bubbles trapped between the layers. Electroblotting was carried out in 1x 
transfer buffer for 1-1.5 h at 150 mA per two gels. Afterwards, membranes were 
incubated in blocking solution for 1 h at room temperature. Immunostaining was 
carried out overnight at 4°C with anti-PDE6A, anti-PDE6B, anti-PDE6D, anti-PDE6G 
antibodies (FabGennix), anti-total AKT, anti-phospho AKT, anti-total ERK, anti-
phospho ERK (Santa Cruz) antibodies. The antibodies were diluted 1:1,000 in blocking 
solution. Later the membranes were washed (3x10 min) with wash buffer and
incubated with the respective HRP (horse radish peroxidase) conjugated polyclonal 
secondary antibodies for 1 h at room temperature. After three final washing steps,
antibodies bound to the proteins on the membrane were detected using enhanced 
chemiluminescence kit (GE Healthcare), according to the manufacturer’s instructions.
Anti-GAPDH (Novus Biologicals) and anti--actin (Abcam) antibodies, diluted at 1:4, 
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000 in blocking solution, were used as internal controls for equal protein loading. For 
this the membrane was striped in preheated 1x stripping buffer. Otherwise when the 
kDa difference between the protein of interest and the internal control allowed, the 
membrane was cut into two parts and processed in parallel for the antibody of interest 
and the internal control antibody.
When necessary, the specificity of the primary antibody was verified by pre-treating 
with blocking peptide. Briefly, antibody was pre-reacted with defined fold excess of 
blocking peptide or PBS (sham). The reactions were vortexed to mix, microfuged 
briefly and incubated overnight at 4°C. Subsequently, the reactions were diluted (1:1, 
000) in blocking buffer. One and the same sample was subjected twice to SDS-PAGE 
gel and parallel immunostaining was carried out with the blocking peptide pre-reacted 
antibody and sham pre-reacted antibody. The band(s) that were competed by the 
blocking peptide pre-reacted antibody, but not sham pre-treated antibody were 
considered specific. Equal protein loading was cross checked with internal control 
antibody (GAPDH) immunostaining. 
3.2.8. Densitometry.
A densitometric analysis was performed to quantify the intensities of each band 
produced from PCR, RT-PCR analysis and immunoblotting. The band intensities were 
quantified using BioDoc analyze 2.1 software (Biometra). The relative intensities of 
target bands were expressed as a proportion of the β-actin or GAPDH bands 
intensities. 
3.2.9. Immunohistochemical staining.
Immunohistochemical staining was carried out with AEC kit (Zymed Laborotories). 
Briefly, serial sections of paraffin-embedded lung tissue slides (3 μm in thickness) were 
pre-warmed at 55°C, dewaxed in xylene and rehydrated through an ethanol series. For 
antigen retrieval the slides were boiled in 1x citrate buffer (pH 6.0) for 20 min and 3% 
H2O2 methanol solution was used to quench the endogenous peroxidase activity. The 
slides were then incubated for 1 h in 10% non-immune goat serum to block non-
specific binding sites. Subsequently, the serial sections were co-stained with anti-
PDE6A (Abcam, 1:200 dilution), anti-PDE6B (Proteintech Group Inc., 1:200 dilution), 
anti-PDE6D (Abcam, 1:200 dilution), anti-PDE6G antibodies (Abcam, 1:200 dilution) 
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and anti-pro-SPC antibody (Chemicon International Inc., 1:1000 dilution). 
Immunohistochemical staining was performed overnight at 4°C. Biotinylated anti-rabbit 
secondary antibody and HRP-streptavidin enzyme conjugate were applied according 
to the manufacturer's instructions. After each incubation step, sections were washed 
briefly in PBS. Development of the reaction was carried out with AEC substrate (red
color) for HRP for 10 min. Finally, sections were counterstained with hematoxylin (blue 
color), mounted in aqueous mounting media (GVA mount) and cover slipped. The 
sections were allowed to dry overnight before examined under a light microscope 
(Leica). 
3.2.10. Cloning. 
Complete gene sequence was RT-PCR-amplified from cDNA, using Pfu DNA
polymerase. The Pfu DNA polymerase enzyme has 3'-5' exonuclease proof reading 
activity hence reduces the errors in nucleotide incorporation during PCR amplification. 
All PCR products were first cloned into pGEMT-easy cloning vector (Promega) by TA-
cloning. Recombinant clones were selected by blue-white screening and thereafter the 
sequence of the clones was confirmed by sequencing using T7 and SP6 vector 
primers, Table IV (appendix). The pGEMT clones confirmed for the insert were 
subcloned into pcDNA3.1/V5-His expression vector (Invitrogen), utilizing the 
advantages of TOPO directional cloning. 
3.2.10.1. PCR amplification of complete gene sequence. 
Primer sequences used for cloning are listed in Table IV (appendix). PCR amplification 
was carried on cDNA samples by use of Pfu DNA polymerase. The reaction mixture 
included:
PCR reaction mix
Reagent Reaction volume (l) Final 
concentration
Pfu DNA Polymerase 10x buffer 
with MgCl2 (20 mM)
5.0 1x
10 pmole/ l FORWARD primer 2.5 1.0 M
10 pmole/ l FORWARD primer 2.5 1.0 M
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dNTP mix (10 mM) 1.0 0.4 mM
Pfu DNA polymerase (2-3 U/ l) 1.0 2.0-3.0 U/ 50 l
ddH2O2 X
DNA template X <0.5 g/ 50 l
Final volume 50
The following PCR profile was used: 
Initial denaturation 94oC 5 min
Denaturation 94oC 1 min
Annealing variable 3 min
Extension 72oC 1 min
Final extension 72oC 10 min
Cycles 30-35
3.2.10.2. Generating ‘A-tailing’ to blunt-ended PCR fragments.
Pfu polymerase enzyme has 3'-5' exonuclease activity hence generates blunt-ended 
PCR fragments. dATP was added at the 3' end of the gel purified PCR product (section 
3.2.10.3) in order to enable TA-cloning of the PCR product into the pGEMT-easy 
vector. 
A tailing reaction
Reagent Reaction volume (µl) Final 
concentration
10x buffer 1.0 1x
MgCl2 (25 mM) 0.5 1.5 mM
dATP (2mM) 1.0 0.2 mM
5 U/ l Taq DNA polymerase 1.0 5 U/ 10 l
PCR product (template) 6.5
Final volume 10
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After incubating the reaction mixture for 30 min at 72°C, the polymerase enzyme was 
inactivated by freezing the reaction mixture. 
3.2.10.3. Ligation of A-tailed DNA Fragment into PGEMT-easy vector.
The isert vector molar ratio was optimized, using the following equation:
ng of vector x kb size of insert x insert:vector molar ration = ng of insert
           kb size of vector
The ligation reaction was set up as described below: 
Ligation reaction mix
Reagent Reaction volume (l)
Final 
Concentration
2x Rapid ligation buffer 5 1x
pGEM-T Easy vector 1
PCR product X
1:3
vector:insert
T4 DNA ligase (3 Weiss U/ l) 1 3 Weiss U/ 10 l
ddH2O2 X
Final volume 10
The reaction mixture was mixed by pipetting, centrifuged briefly and incubated 1 h at 
room temperature. Then T4 DNA ligase in the ligation mix was heat inactivated for 20 
min at 65°C.
3.2.10.4. Heat shock transformation. 
Chemocompetent JM109 cells (Promega) were thawn on ice for 5-10 min. For a single 
transformation 1 aliquot (50 μl) of JM109 cells suspension was added to 3-5 μl of the 
ligation reaction mix in an eppendorf tube, equalling approximately 1-10 ng of circular 
plasmid DNA. Immediately after heat shock (45 s at 42°C) the tube was placed on ice 
for 2 min. After adding 450 μl of SOC medium, the tubes were incubated at 37°C for 
1.5 h with shaking (150 rpm). The transformation reaction was spread in 100 μl 
volumes onto selective bacterial agar plates (50 μg/ml ampicillin, 100 M IPTG, 50 
g/ml X-gal). An ethanol flamed glass-hockey stick was used for even distribution of 
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bacterial cultures. Plates were incubated overnight at 37°C. 
3.2.10.5. pGEMT easy recombinant clone selection. 
Successful cloning of an insert into pGEMT- easy vector interrupts the coding 
sequence (lacZ) of β-galactosidase (Figure A1 (appendix)). White colonies are 
indicative for vector containing insert and were subjected to a colony screen. 
3.2.10.6. Small scale plasmid DNA purification.
Plasmid DNA was prepared in small scale using Qiagen spin miniprep kit. The 
principle of this kit is based on alkaline lysis of bacteria cells followed by adsorption of 
DNA onto a silica column. 
Briefly, pick a single white colony using a sterile toothpick and use to innoculate 2-5 ml 
selective LB medium (50 μg/ml ampicillin). Grow bacterial cultures overnight in a 37°C
incubator with shaking (220-300 rpm). Then collect bacteria by centrifugation at 6000 x 
g for 1 min at 4°C. Resuspend the bacterial pellet in 250 l buffer P1 (containing 
RNase A). Then add 240 l buffer P2 and gently invert the tube 4-6 times to mix. Then 
add 350 l Buffer N3 and invert the tube immediately but gently 4-6 times. Centrifuge 
for 10 min at maximum speed. Then add the supernatant to the QIAprep spin column 
and centrifuge again. After add 500 l buffer PB and centrifuge. Wash QIAprep spin 
colum by adding 750 l buffer PE. Centrifuge twice to remove residual wash buffer. 
After, place the column in a clean 1.5 ml eppendorf tube and add 50 l buffer EB or 
ddH2O2. Incubate 2-3 min and collect plasmid DNA with centrifugation. Further plasmid 
DNA was sequenced and used for directional TOPO cloning. 
3.2.10.7. Directional TOPO cloning in pcDNA 3.1 vector.
In order to anneal with the -GTGG- overhang of the pcDNA 3.1 directional TOPO 
expression vector (Figure A2 (appendix)), the forward primer was modified at the 5’ 
end to contain a corresponding 4-bp CACC sequence. The reverse primer was 
designed in such a way that the stop codon was ignored so as to ensure the presence 
of C terminal His-tag expression. PCR amplification was carried on 10-100 ng purified 
plasmid DNA samples, using Pfu DNA polymerase as described (section 3.2.10.1). 
The principle of directional TOPO cloning is given in Figure A3 (appendix).
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3.2.10.8. TOPO cloning reaction.
For cloning in pcDNA3.1 directional TOPO expression vector the following reaction 
was prepared:
TOPO cloning reaction mix
Reagent Reaction volume (l)
JM 109 cells (>108 cfu/ g) 50
Fresh PCR product X
Salt solution 1.0 
TOPO vector 1.0 
ddH2O2 X 
Final volume X
The rection was mixed gently and incubated for 5-30 min at room temperature. After 
the TOPO cloning reaction mix was subjected to heat shock transformation (section 
3.2.10.4)
3.2.10.9. pcDNA 3.1 clone analysis.
Individual recombinant clones were analyzed by restriction analysis and sequencing 
with primers listed in Table IV (appendix). pcDNA3.1/V5-His-TOPO vector does not 
contain β-galactosidase gene sequence for blue-white screening (Figure A2 
(appendix)). 
3.2.10.10. Large scale endotoxin free plasmid extraction.
Plasmid DNA was prepared in large scale using Qiagen endofree plasmid maxi kit. 
Large scale plasmid DNA isolation is based on the same strategy as miniprep 
isolation: alkaline lysis of bacteria cells followed by adsorption of DNA onto a silica 
column. 
Briefly, innoculate a single colony with 2-5 ml selective LB medium (50 g/ ml 
ampicillin). Incubate for 6-8 h in a 37°C incubator with shaking at 220-300 rpm. Then 
dilute the starter culture 1/500 to 1/1000 into selective LB medium (50 g/ ml 
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ampicillin). Grow overnight (37°C, 220-300 rpm). Collect bacteria by centrifugation at 
6000 x g for 15 min at 4°C. Resuspend the bacterial pellet in 10 ml pre-warmed buffer 
P1. Add 10 ml buffer P2, mix gently and incubate at room temperature for 5 min. Then 
add 10 ml of chilled buffer P3, mix immediately. Pour the lysate into the barrel of the 
QIAfilter cartridge. Incubate for 10 min and filter through the cartridge using plunger. 
Then add 2.5 ml of buffer ER to the filtered lysate, mix by inverting the tube and 
incubate on ice for 30 min. Then apply the filtered lysate to an equilibrated QIAGEN-tip 
(2x 10 ml buffer QBT) and allow it to enter the resin by gravity flow. Wash the 
QIAGEN-tip with 2 x 30 ml of buffer QC. Elute DNA with 15 ml buffer QN. Then 
precipitate DNA by adding 0.7 volumes of room temperature isopropanol. Mix and 
centrifuge immediately at  15 000 x g for 30 min at 4°C. Wash the resultant pellet 
twice with 70% endotoxin free ethanol and air dry at room temperature. The pellet is 
carefully resuspended in a suitable volume of endotoxin-free buffer TE and used for 
transfection of cultured mammalian cells. The endotoxins removal step with ER buffer 
is essential for optimal transfection efficiency and high reproducibility of results. 
3.2.10.11. Glycerol stock.
For storage of recombinant clones, 500 l of an overnight bacterial culture were mixed 
throughly with 500 μl of 100% glycerol in a 1.5 ml ependorff tube. This 50% glycerol 
stock solution was subsequently frozen at –80°C.
3.2.11. siRNA
Endogeneous PDE6D expression was knockdowned with PDE6D siRNA target 
sequence (Eurogentec, Seraing, Belgium, 100 nM). Negative control siRNA sequence 
(Eurogentec, Seraing, Belgium, 100 nM) was used as a specificity control.
3.2.12. Cell culture.
A549 human AEC line was obtained from American Type Culture Collection 
(Manassas, VA). The cells were propagated and maintained in complete DMEM F12 
medium in a humidified atmosphere with 5% CO2 and 95% air. The antibiotics were 
excluded from the growing medium to avoid possible side effects on cell metabolism, 
differentiation and viability. The utilized transfection protocol as well required antibiotic-
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free medium. Cellular growth and viability were assessed by phase contrast 
microscopy. The culture medium was replaced every other day. After attaining 
confluence, medium was aspirated from the cells, the cells were washed with PBS (2x 
times) and trypsinized with 1x trypsin-EDTA solution,diluted in 1x PBS. The trypsin-
EDTA solution was neutralized with complete DMEM F12 medium. For experiment 
purposes, A549 cells were seeded at density 2x105/ml, which gave 80% confluence in 
24 h. All the solutions added to cell cultures were pre-warmed in a 37°C water bath. All 
manipulations were performed aseptically in a cell culture hood using sterile 
equipment.
Primary human ATII cells: were isolated after the lungs had been preserved for 4–8 h 
at 4°C. The pulmonary artery was perfused with a 37°C PBS solution, and the distal air 
spaces were lavaged with pre-warmed Ca2+ - and Mg2+ -free PBS solution (0.5 mM
EGTA and 0.5 mM EDTA) 10 times. Next, 13 U/ml elastase in Ca2+ - and Mg2+ -free 
HBSS were instilled into the distal air spaces through segmental bronchial intubation. 
After digestion for 45 min, the lung was minced finely in the presence of FBS and
DNase (500 g/ml). The cell-rich fraction was filtered by sequential filtration through 
one layer of sterile gauze, two layers of gauze, and 150 m and 30 m nylon mesh. 
The solution was then layered onto a discontinuous Percoll density gradient 1.04 –1.09 
g/ml solution and centrifuged at 1,500 rpm for 20 min. The upper band containing a 
mixture of type II pneumocytes and alveolar macrophages was collected and 
centrifuged at 800 rpm for 10 min. The cell pellet was washed and resuspended in 
Ca2+ - and Mg2+ -free PBS containing 5% FBS. The cells were then incubated with 
magnetic beads coated with anti-CD-14 antibodies at 4°C for 40 min under constant 
mixing. Then the beads were depleted with a Dynal magnet (Dynal Biotech, Oslo, 
Norway). The remaining cell suspension was incubated in human IgG-coated tissue 
culture-treated Petri dishes in a humidified incubator (5% CO2, 95% air) at 37°C for 90 
min. Unattached cells were collected and counted. Cell viability was assessed by the 
trypanblue exclusion method. The purity of isolated human AT II cells was examined 
by Papanicolaou staining [232]. 
3.2.12.1. Cryopreservation and thawing of cell cultures.
Cultured cells were cryopreserved by resuspending the harvested pellet in freeze 
medium. The cells were transferred to a cryogenic vial and immediately placed in a -
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80°C freezer overnight before transfer to -195°C liquid nitrogen for long term storage. 
Vials removed from liquid nitrogen were thawed rapidly in a 37°C water bath and cells 
were immediately rinsed twice in growth medium to remove the freeze medium.
3.2.13. Transient transfection.
Cells were transiently transfected using lipofectin 2000 reagent (Invitrogen), a 1:1 
(w/w) liposome formulation of the cationic lipid N-[1-(2,3-dioleyloxy)propyl] 
n,n,ntrimethylammonium chloride (DOTMA) and dioleoyl phosphotidylethanolamine
(DOPE) in membrane filtered water.
Cells were maintained as described (Section 3.2.12). 80% confluent cells were used 
for the transfection experiments. On the day of transfection, plasmid DNA or siRNA
were diluted in Opti MEM-I +glutaMax-I medium (Gibco). Separately, Lipofectin 2000
reagent (Invitrogen) was diluted in Opti MEM-I +glutaMax-I medium. The diluted 
plasmid DNA/ siRNA and the diluted lipofectamine 2000 reagent were pre-incubated at 
room temperature for 5-10 min before being mixed to make complexes. Complexes
were allowed to form for a further 15 min at room temperature. Complexes were finally 
diluted with 0.1% DMEM F12 medium which in turn was added onto cells that had 
been washed with 2 ml of OPTI-MEM I. After 5-6 h, this medium was replaced with 
complete DMEM F12 medium. Cells were analysed after a given time point.
Transfection volumes were scaled up or down according to the surface area of the 
tissue culture vessel in use (Lipofectamine 2000 reagent, Invitrogen, data sheet).
3.2.13.1. Transient transfection efficiency assessment.
For overexpression studies, transfection efficiency was monitored with anti-PDE6D 
(FabGennix) and anti His-HRP conjugate (Clontech) antibodies. For siRNA-mediated 
inhibitory studies, transfection efficiency was assessed with anti-PDE6D (FabGennix) 
antibody. 
3.2.14. Measurement of cell proliferation.
A549 cells were transfected under starvation conditions for 6 h, rendered quiescence 
for 24 h in 0.1% FBS DMEM F12 medium and then subjected to serum stimulation for 
24 h. The effects on cell growth were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide (MTT) and [3H]-Thymidine incorporation assay.
3.2.14.1. MTT cell proliferation assays.
MTT (3-4,5-dimethylthiazol-2,5 diphenyl tetrabromide) is reduced in viable cells by 
mitochondrial dehydrogenase to a purple coloured crystal, formazan, allowing cell 
viability to be determined by a colourimetric assay.
Cells (2x105/ ml) were seeded in 96-well plates. For the last 4 h of proliferation 
experiments, cells were stained with 0.05 mg/ ml of MTT solution per well at 37°C. 
Medium was aspirated and the wells were incubated with 100 μl of 0.04N HCL solution 
in isopropanol for 15-20 min at 37°C. This allowed complete solubilization of the 
converted dye (formazan). The absorbance of each well was then read in a ELISA 
reader (Tecan) at 570 nm wavelength. 
3.2.14.2. [3H]-Thymidine incorporation assay.
Tritiated [3H]-Thymidine is incorporated into cellular DNA during S-phase of DNA 
synthesis, allowing radioactive monitoring of cell proliferation rate. Cells (2x105/ ml) 
were seeded in 48-well plates. For the last 4 h of proliferation experiments, cells were 
labeled with 0.1 Ci [3H]-Thymidine per well at 37°C. Medium was aspirated and cells 
were washed with 500 l ice cold HBSS (2x times). Next, cells were fixed in 250 l ice 
cold methanol for 15 min at 4°C. Without aspiration step, 250 l 10% TCA solution was 
added to the wells to precipitate nucleic acid polymers. TCA incubation was kept for 15 
min at 4°C. Cells were washed extensively with sterile H2O2 (Aqua B Braun) and 
solubilized in 0.1 M NaOH. The [3H]-Thymidine content of the cell lysates was 
determined by scintillation counting (Canberra -Packard). 
3.2.15. Statistical analysis.
All data were expressed as the means  S.E. Data were compared using a two-tailed 
Student’s t-test, or a 1-way ANOVA with the Student-Newman- Keuls post hoc test for 
studies with more than 2 groups. Statistical significance was assumed when P<0.05. 
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IV. Results.
4.1. mRNA expression profile of cGMP PDEs in IPF lungs.
We used semi-quantitative RT-PCR to analyse the mRNA expression profile of 
cGMP PDEs in lung tissue samples of donors and IPF patients. Initially, we 
assessed the mRNA expression levels of PDE1A, PDE1B, PDE1C, PDE2A, 
PDE5A, PDE9A, PDE10A and PDE11A. Despite of the intergroup individual 
differences significant upregulation was detected for PDE1A and upregulation 
tendency was observed for PDE10 and PDE11 in the IPF lungs as compared to 
donor lungs (Figure 11 a, b). 
Donors IPF
PDE1A
PDE1B
PDE1C
GAPDH
β Actin
PDE2A 
PDE5A
PDE9A
PDE10A
PDE11A
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Figure 11. mRNA profile of cGMP PDEs in lung tissue samples of donors and IPF patients. 
a) Semi-quantitative RT-PCR analysis was used to assess cGMP PDE expression in lung tissue samples of donors (n=3) and IPF 
patients (n=3). GAPDH served as an internal control for equal loading. b) Corresponding densitometric quantification, normalization 
was carried out with respect to GAPDH expression, □ donor and ■ IPF lungs.
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4.2. mRNA detection of the PDE6 enzyme subunits in lung tissue samples of 
donors and IPF patients.
The mRNA expression of each PDE6 subunit in lung tissue samples of donors and 
IPF patients was analyzed by a semi-quantitative RT-PCR technique. As illustrated 
in Figure 12a, all PDE6 mRNAs were RT-PCR amplified. Parallel minus-RT control 
reactions were carried out to exclude the possibility of genomic DNA contamination. 
The densitometric analysis indicated moderate mRNA alterations of PDE6B, 
PDE6D and PDE6H genes in the IPF lungs compared to the donor lungs (Figure 
12b). The resulting PCR products were validated by direct sequencing, followed by 
BLAST analysis that confirmed the similar sequence alignment for each subunit 
(Figure 12c).
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Figure 12. PDE6 mRNA detection in lung tissues from donors and IPF 
patients.
a) Semi-quantitative RT-PCR analysis was used to assess PDE6 expression in 
lung tissues from donors (n=3) and IPF patients (n=3), minus-RT control reactions 
excluded genomic DNA contamination. b) Corresponding densitometric analysis 
normalized to GAPDH expression, □ donor and ■ IPF lungs, *P<0.05. c) Sequence
alignment of the PDE6 subunits. 
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4.3. Protein expression of the PDE6 enzyme subunits in lung tissue samples 
of donors and IPF patients.
The protein content of the PDE6 subunits in lung tissue samples of donors and IPF 
patients was quantified by immunoblotting. As illustrated in Figure 13
immunoreactivity was detected for all PDE6 proteins: PDE6A (105 kDa), PDE6B 
(105 kDa), PDE6G (11 kDa) and PDE6D (17 kDa) subunits. Pig retinal lysate
served as a possitive control for immunoreactivity and proper protein size. 
Additionally, PDE6A and PDE6B blocking peptide studies reconfirmed the PDE6A 
and PDE6B lung immunoreactivity (Figure 13c, d). Notably, the protein content of 
PDE6 varied between donor and IPF-derived lung tissues. PDE6A and PDE6B 
exhibited a 2 fold up-regulation (Figure 13a, b), PDE6D a 2 fold down-regulation 
(Figure 13c, d) and PDE6G membrane localization (Figure 13e, f) in the IPF lungs 
as compared to donor lungs. 
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Figure 13. PDE6 immunoreactivity in lung tissues from donors and IPF 
patients.
a) Western blotting analysis was used to assess PDE6 expression in lung tissues 
from donors (n=4) and IPF patients (n=4), pig retinal lysate was used as a positive 
control (C+) for PDE6 immunoreactivity. b) Corresponding densitometric analysis, 
normalized to GAPDH expression, □ donor and ■ IPF lungs, *P<0.05. c) 
Demonstration of PDE6A and PDE6B antibodies’ specificity by an antigen 
(peptide/protein) blocking technique. d) Corresponding densitometric analysis 
normalized to GAPDH expression, BP ( blocking peptide, □ without BP and ■ with 
BP. e) Total and fractionated cytosolic and membrane proteins which were 
immunoblotted with PDE6G antibody. f) Corresponding densitometric analysis 
normalized to -actin expression , □ donor and ■ IPF lungs.
4.4. Cellular localization of the PDE6 enzyme subunits in lung tissue samples 
of donors and IPF patients. 
The cellular localization of the PDE6 subunits was assessed by serial 
immunohistochemical stainings on tissue sections from donor and IPF lungs. As 
shown in Figure 14, PDE6A, PDE6B, PDE6D and PDE6G were co-stained with 
pro-SPC, suggesting the presence of PDE6 subunits in the ATII AECs. PDE6A and 
PDE6D immunoreactivity was recognized in the cytoplasm, PDE6B 
immunoreactivity in the nuclei and PDE6G immunoreactivity in the membrane of 
ATII cells.
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Figure 14. Immunohistochemical localization of PDE6 in lung sections from 
donors and IPF patients. 
Immunohistochemical stainings were performed on serial tissue sections of donor 
(upper row) and IPF (bottom row) lungs. PDE6A, PDE6B, PDE6D and PDE6G 
were co-stained with pro-SPC, a marker specific for ATII cells. PDE6A and PDE6D 
immunoreactivity was recognized in the cytoplasm, PDE6B immunoreactivity in the 
nuclei and PDE6G immunoreactivity in the membrane of ATII cells. The red and 
dark brown color is indicative of immunoreactivity. Tissue slides were 
counterstained with hematoxylin (blue color). Negative control stands for no 
antibody reaction, magnification 400x.
4.5. The PDE6 enzyme subunits are expressed in human ATII cells.
To confirm this cellular localization pattern, the PDE6. subunits were RT-PCR 
amplified from human primary donor and IPF-derived ATII cells. All PDE6 subunits 
(except for PDE6C) were found expressed by these cells. Densitometric 
normalization to GAPDH expression revealed significantly decreased mRNA levels 
of the PDE6D subunit in IPF-derived ATII cells (Figure 15a). Importantly, 
independent densitometric normalization to pro-SPC (AECs specific marker) 
reconfirmed the downregulation pattern of PDE6D in ATII cells from IPF patients
(Figure 15b). Supplementary, we showed that the mRNAs of all PDE6 subunits 
(except for PDE6C and PDE6H) and the complete set of PDE6 proteins (PDE6A, 
PDE6B, PDE6D and PDE6G) are expressed in A549 cells (Figure 15c, d). 
Considering the facts that (i) the A549 cells possess ATII cell phenotype and (ii) 
transient transfection of primary isolated ATII cells continues to be largely 
inefficient, we used this cell line for further functional experiments.
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Figure 15. The PDE6 enzyme subunits are expressed in human ATII cells.
Semi-quantitative RT-PCR was used to assess PDE6 expression in human primary 
donor and IPF-derived ATII cells. a) Densitrometric analysis of PDE6 subunits 
expression normalization was carried out with respect to GAPDH expression, □ 
donor ATII cells and ■ IPF-derived ATII cells, *P<0.05. b) Densitometric analysis of 
PDE6 subunits expression, normalization was carried out with respect to proSP-C 
expression, □ donor ATII cells and ■ IPF-derived ATII cells, *P<0.05. c) mRNA 
expression profile of PDE6 subunits in A549 AECs, M DNA molecular marker. d) 
Protein expression profile of PDE6 subunits in A549 AECs. 
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4.6. Effects of PDE6D modulations on A549 cell proliferation. 
Further, we studied the effects of PDE6D downregulation in A549 cells. siRNA 
silencing of PDE6D resulted in a significant loss of PDE6D protein expression 24 
and 48h post transfection. The negative control siRNA caused no change in 
PDE6D protein expression (Figure 16a). The loss of PDE6D expression was 
coupled to a slightly decreased MTT conversion (Figure 16b) and a significantly 
decreased [3H]-Thymidine uptake (Figure 16c) as compared to control siRNA and 
no siRNA transfected cells 24 h post serum stimulation. Complementary, transient 
overexpression of PDE6D in A549 cells resulted in a significantly enhanced 
PDE6D expression and detection of PDE6D His-tagged protein 24 and 48 h post 
transfection. Empty vector transfection caused no change in PDE6D protein 
expression (Figure 17a). The gain of PDE6D expression was coupled to a slightly 
increased MTT conversion (Figure 17b) and a significantly increased [3H]-
Thymidine uptake (Figure 17c) as compared to empty vector expressing cells and 
no DNA transfected cells 24 h post serum stimulation.
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Figure 16. Knockdown of endogenous PDE6D expression decelerates the 
proliferation rate of human A549 AECs.
a) Demonstration of PDE6D knockdown in A549 cells: upper panel: decreased 
PDE6D immunoreactive protein 0-48 h post transfection with 100 nM PDE6D 
siRNA. The negative control siRNA (100 nM) caused no change in PDE6D protein 
expression. The bottom panel represents GAPDH used as a control for equal 
protein loading. b) Bar graph presentation of MTT conversion in PDE6D siRNA 
transfected cells 24 h post serum stimulation. Data were expressed as % of 
control. Serum stimulation was significant #P<0.001. c) Bar graph presentation of 
[3H]-Thymidine uptake in PDE6D knockdown cells 24 h post serum stimulation. 
Data were expressed as cpm/ x105 cells. Serum stimulation was significant 
#P<0.001. [3H]-Thymidine uptake of PDE6D knockdown cells was significantly 
decreased as compared to control siRNA transfected cells (*P<0.001) and no 
siRNA transfected cells (only lipofectamine (Lf)) (†P<0.001). Lipofectamine
concentration was kept constant throughout the experimental settings and had no 
effect on cell viability (P= 0.2699). 
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Figure 17. Overexpression of PDE6D accelerates the proliferation rate of 
human A549 AECs.
a) Demonstration of PDE6D overexpression in A549 cells: upper panel: increased 
PDE6D immunoreactive protein 0-48 h post transfection with pcDNA3.1/His-
PDE6D vector. These expressional changes were not observed in pcDNA3.1/His-
lacZ empty vector transfected or no DNA transfected cells (only lipofectamine (Lf)). 
Middle panel: The membrane was probed with anti –C-His antibody. A band of 
approximately 23 kDa was detected in the pcDNA3.1/His-PDE6D transfected cells 
but not in the pcDNA3.1/His-lacZ empty vector transfected or no DNA transfected 
cells (only lipofectamine (Lf)). The bottom panel represents GAPDH used as a 
control for equal protein loading. b) Bar graph presentation of MTT conversion in 
PDE6D overexpressing cells 24 h post serum stimulation. Data were expressed as 
% of control. Serum stimulation was significant #P<0.001. c) Bar graph 
presentation of [3H]-Thymidine uptake in PDE6D overexpressing cells 24 h post 
serum stimulation. Data were expressed as cpm/x105 cells. Serum stimulation was 
significant #P<0.001. [3H]-Thymidine uptake of PDE6D overexpressing cells was 
significantly increased as compared to pcDNA3.1/His-lacZ empty vector 
transfected (*P<0.01) and no DNA transfected cells (only lipofectamine (Lf)) 
(†P<0.01). Lipofectamine concentration was kept constant throughout the
experimental settings and had no effect on cell viability (P= 0.3552), EV empty 
vector.
4.7. PDE6D knockdown inhibits ERK phosphorylation.
We then, opted to explore signaling pathways related to PDE6D-mediated 
proliferative responses. In particular, we studied the effects of PDE6D 
downregulation on serum induced phosphorylation of ERK and AKT proteins in 
A549 cells. Downregulation of PDE6D by siRNA was found to suppress serum-
induced phosphorylation of ERK 24 h post stimulation compared to control siRNA.
Whereas, PDE6D had no effect on the phosphorylation status of AKT (Figure 18 a-
c).
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Figure 18. PDE6D siRNA knockdown inhibits serum stimulated ERK 
phosphoprylation.
a) Western blot analysis of kinase proteins associated with PDE6D knockdown 
effects in serum stimulated A549 cells (24 h time point), GAPDH is a loading 
control. b) densitometric analysis of ERK phosphorylation normalized to total ERK. 
c) Densitometric analysis of AKT phosphorylation normalized to total AKT. Data are 
representative for two independent experiments.
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CHAPTER 5: DISCUSSION
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V. Discussion
5.1. mRNA profile of cGMP PDEs in lung tissue samples of donors and IPF 
patients.
IPF is an unresolved clinical issue. This situation demands a better understanding 
of the molecular and cellular mechanisms involved in the pathogenesis of IPF. The 
members of the PDE superfamily, PDE1, PDE2, PDE3, PDE4 and PDE5 are highly 
expressed in the lung and have been shown to potentially contribute to the 
pathogenesis of various lung diseases [153-156, 233-235]. Nevertheless, 
information regarding plausible PDEs contribution into IPF pathogenesis is lagging 
behind. Several reports have shown the positive effects of the PDE5 inhibitor, 
sildenafil on the pulmonary hemodynamics and walk distance capacities in patients 
with pulmonary fibrosis [160, 231]. This brings up an important question whether 
other cGMP PDEs have a potential relevance to pulmonary fibrosis. Thus the first 
aim of the present study was to characterize the mRNA expression profile of cGMP 
PDEs in lung tissue samples of donors and IPF patients. mRNA levels of PDE1A, 
PDE10A and PDE11A were found increased in the IPF lungs as compared to 
donor lungs (Figure 11a, b). These mRNA alterations need to be further explored
and confirmed on protein level. Characterization of the cellular and subcellular 
localization patterns of cGMP PDEs in donor and IPF-derived lungs is of interest
for future studies, aiming to delineate the functional contribution of these enzymes 
into IPF pathogenesis.
5.2. Detection of PDE6 enzyme subunits in lung tissue samples of donors 
and IPF patients.
PDE6 expression and function are thought to be confined to the the retina. PDE6 is 
extensively studied in the context of retinal degenerative diseases. Nevertheless, 
reports show that PDE6 might have roles in circadian rhythms in avian pineal gland 
[236] and that PDE6 activity may be involved with wnt signalling and zebrafish 
development [237]. Studies regarding lung PDE6 expression and function,
however, are lagging behind. Herein, we report previously unrecognized PDE6 
expression in the human lung, as evidenced by mRNA and protein detection of all 
rod and cone subunits, encoding the PDE6 multi-component enzymes (Figure 12, 
13). Interestingly, the PDE6 subunits were found differentially altered in the IPF 
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lungs, with PDE6A and PDE6B 2-fold up-regulated, PDE6D 2-fold down-regulated 
and PDE6G membrane localized, suggesting a plausible contribution of PDE6 to 
the pathogenesis of IPF (Figure 13).
To our knowledge this is the first report that has described the expression and 
characterization of PDE6 isoforms in both the physiology and pathophysiology of 
the lung. This finding is further supported by the reports that have demonstrated 
solitary PDE6 subunit expression in a variety of non-retinal tissues. The rod 
catalytic PDE6A and PDE6B subunits were found to be weakly expressed in brain 
[238, 239]. Piriev et al. demonstrated that the catalytic core of the rod PDE6 
enzyme (PDE6A and PDE6B subunits) can be synthesized in human kidney cells 
with consequent expression of enzymatic activity [240]. The inhibitory and the 
regulatory PDE6G and PDE6D subunits, respectively, have been reported to be 
expressed in a variety of heterogeneous tissues, including the lung [225, 241]. 
5.3. PDE6 enzyme subunits expression in human AECs.
Based on immunohystochemical data all PDE6 subunits were co-stained with pro-
SPC, suggesting the presence of PDE6 subunits in the ATII AECs (Figure 14). 
Furthermore this cellular localization pattern was confirmed by RT-PCR 
amplification of the PDE6 subunits from human primary donor and IPF-derived ATII 
cells (Figure 15). Thus, we believe that PDE6 alterations (subsequent cGMP 
alterations) may play a crucial role in epithelial apoptosis, proliferation, surfactant 
synthesis and ROS generation. cGMP modulation is further supported by recent 
reports in the literature that suggest the beneficial effects of sildenafil, a PDE5 
inhibitor, in experimental models of pulmonary fibrosis and IPF secondary to PAH 
[160, 161]. Considering the fact that sildenafil not only inhibits PDE5, but also 
PDE6 (9 fold less) [242], we believe that the attenuation of pulmonary fibrosis in 
sildenafil treated mice may be also due to its inhibition of PDE6. 
Interestingly the PDE6 subunits displayed different sub-cellular localization pattern. 
PDE6A and PDE6D immunoreactivity was recognized in the cytoplasm, PDE6B 
immunoreactivity in the nuclei and PDE6G immunoreactivity in the membrane of 
ATII cells (Figure 14). The nuclear staining of PDE6B is suggestive for PDE6B 
playing a role as a transcriptional factor in the alveolar epithelium. The 
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membraneous staining of PDE6G corroborates with the membrane localization 
pattern of this subunit in IPF-derived lungs. PDE6G has been reported to function 
as an important intermediate to regulate mitogen-activated ptotein kinase (MAPK) 
pathway in animal and cellular models of hypoxia-mediated pulmonary 
hypertension [243]. PDE6G has been shown to affect receptor internalization-
dependent MAPK activity and EGF stimulated/ G-protein coupled receptor kinase 2 
(GRK2) mediated MAPK activity in human embryonic kidney 293 cells [244, 245]. 
Additionally, the PDE6G subunit has been shown to modulate the proteolysis of 
PDE5 by caspase-3 in mouse lung and testis [246]. Thus, we could predict that 
PDE6G detected in the lung alveolar epithelium and membrane-localized in IPF-
derived lungs might affect AEC proliferation, apoptosis and/or transdifferentiation.
5.4. Functionality of PDE6.
Although at present the physiological roles of the rod and cone PDE6 enzymes in 
the lung are unknown and the functionality of PDE6 enzyme in IPF needs to be 
confirmed, the study of Wang et al. [220] does provide evidence for the presence 
of functional PDE6 enzyme in non-retinal tissues. The authors claimed PDE6 to be 
an effector for the Wnt/Ca2+/cGMP signalling pathway in development, which is
mediated by Frizzled-2 receptors. Supplementary, the study of Ma L et al.
describes a central role of PDE6 in Wnt5a mediated cGMP responses [247].
To carry out studies on the structure and function of PDE6 in normal and diseased 
conditions of the lung, each of the biologically active subunits of the enzyme is 
necessary. Our immunohystochemical data (Figure 14) are suggestive for possible
PDE6 complex assembly in ATII cells. Nevertheless, analysis of a functional PDE6 
assembly is tricky, considering the unique characteristics of these enzymes. 
Moreover, research carried out in bacteria and in yeast systems have failed to yield 
expression of functional PDE6 complexes that have all of the properties of the 
native enzymes [248-252]. 
Interestingly, there is evidence of independent catalytic activity of PDE6 subunits 
from bovine heart and adrenal cortex [253]. In line, Piriev et al. have demonstrated
that the PDE6A and PDE6B subunits can be synthesized in human kidney cells 
with consequent expression of enzymatic activity. In deed, the domain organization 
of PDE6A and PDE6B subunits is suggestive for their independent cGMP-
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hydrolytic activity. This is of particular importance since this may mean that rod
PDE6 subunits in the lung may be present and functional not only as β
heterotetramer, but also as  and ββ complexes. PDE6 of other tissues have 
this type of composition. For example, the catalytic subunit of cone cGMP-PDE 
exists as a homodimer, ’’ [254], and the catalytic and allosteric domains of PDE6
from bovine heart and adrenal cortex are also homodimeric [253]. 
Intriguingly, a significant body of research shows that recessive retinitis pigmentosa 
is associated with mutations in the PDE6A and PDE6B genes [255, 256]. In line, 
an absence of PDE6 activity accompanied by elevation of cGMP levels had been 
described in animal models of retina degeneration. Rapid photoreceptor 
degeneration is ensued in mice by a recessive nonsense mutation in the PDE6B 
subunit (rd1 mice). A defect in the corresponding canine PDE6B subunit gene 
causes another retinal degenerative disorder (rcd1) in Irish setters, and a defect in 
the PDE6A subunit gene in Cardigan Welsh corgi dogs (rcd3) generates a similar 
phenotype [222]. We could speculate that mutations in the PDE6A and PDE6B 
genes might be associated with inherited form of IPF and that these mutations 
might increase the susceptibility to IPF development. 
5.5. Individual functional capacity of PDE6D.
The individual functional capacity of the specific PDE6D subunit has been widely 
speculated in the literature. PDE6D functionality is mainly linked to its prenyl 
protein binding properties. It is assumed that PDED interacts with proteins that 
carry COOH-terminal CAAX sequence in two distinct ways: 1) through a lipid 
binding pocket and 2) -sheet/-sheet interactions [227]. The list of PDE6D 
interacting partners comprises of: PDE6A and PDE6B catalytic subunits of the rod 
PDE6 enzyme, rhodopsin kinase, the  subunit of transducin, lamins A and B, the 
subunits of heterotrimeric G proteins, [257], small GTPases of the Ras superfamily, 
including Ras and Rap [221], Rho6 and Rheb [227], and Rab8 [214]. 
The Ras/ERK and Ras/AKT signaling pathways mediate the proliferation and 
differentiation of many cell types [258-261]. ERK activation has been shown to be 
of critical importance for ATII cell proliferation [261]. ERK signaling has also been 
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documented to regulate differentiation of fetal ATII cells [262]. Akt signaling has 
been implicated in lipogenesis pathways required for surfactant protein synthesis 
[263, 264]. Additionally, AKT activation has been shown to have a protective 
function in the context of lung injury [265]. These observations led us to 
hypothesize that PDE6D might regulate the proliferation rate of ATII cells. 
We were able to show that PDE6D exerts pro-proliferative effects in AECs, as 
deduced from PDE6D siRNA-mediated knockdown and overexpression studies in 
an A549 human AEC line (Figure 16, 17). Further, our study indicates that PDE6D 
mediated proliferative responses are related to ERK phosphorylation status. siRNA 
mediated inhibition of PDE6D decreased the serum induced phosphorylation of 
ERK (Figure 18). Thus, we propose PDE6D as a critical regulator of ERK mediated 
ATII cells proliferation. This functional property of PDE6D is significant, considering 
its c-Myc/E2F4 controlled expression. In line with our hypothesis, PDE6D (-/-) mice 
are consistently smaller in size, indicating a plausible involvement of PDE6D in
growth arrest [266]. Thus, it can be imagined that the proliferative phenotype of 
IPF-derived ATII cells is associated with the observed PDE6D depletion in IPF 
lungs. 
Based on the unique functional properties of the PDE6D subunit, it is tempting to 
further speculate that the PDE6D subunit itself might directly affect the rate of 
cGMP hydrolysis. The study of Cook TA et al.,in deed, does demonstrate that
PDE6D can modify cGMP hydrolytic activity in preparations of broken rod outer 
segments and that these effects might be due to PDE6D ruled solubilization of 
PDE6, involving functional uncoupling of transducin [267].
5.6. Summary points.
cGMP PDEs are key enzymes in cellular signaling pathways. Several lines of 
evidence have underlined the broad therapeutic potential of cGMP PDE inhibitors. 
PDE5 inhibitors such as sildenafil, tadalafil and vardenafil have had distinctive 
clinical benefit and notable commercial success. Thus, the topic questioned in the 
present PhD thesis “Role of cGMP PDEs in IPF is of significant importance. The 
data shown demonstrate that:
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1. Multiple cGMP PDE isoenzymes are expressed in human lung.
2. PDE1A and PDE10A and PDE11A mRNA expression is alterated in IPF lungs 
as compared to donor lungs.
3. PDE6 mRNAs and proteins are expressed in human lung.
4. Protein levels of the individual PDE6 subunits are differentially altered in IPF 
lungs as compared to donor lungs: 
5. The individual PDE6D subunit has a specific functional role in AEC proliferation 
(siRNA – mediated knockdown and ectopic expression studies)
6. PDE6D effects on AEC proliferation are related to ERK phosphorylation (siRNA-
mediated knockdown studies).
5.7. Future issues.
The present report opens up numerous questions in specific need to be addressed 
in future studies: 
(1) The physiology of rod and cone PDE6 enzymes in the retina is remarkably 
distinct. Rod PDE6 provides for the scotopic vision and cone PDE6 provides for the 
photopic vision. More specific research is required to characterize the physiological 
roles of rod and cone PDE6 subunits in the lung. Can rod and cone PDE6 subunits 
govern different physiological process in the lung? Do they have same, different or 
opposing functions in the lung? Cone PDE6 subunits are 10-fold less abundant 
than rod PDE6 subunits in the photoreceptors. However, vison alterations in color 
perception, reported following sildenafil usage are suggestive for preferential
targeting of cone PDE6 [268]. Logistically, what is the susceptibility of rod and cone 
PDE6 subunits, expressed from lung, to PDE5-targeted drugs? Are cone PDE6 
subunits more sensitive? Attempts to address these questions might utilize the 
already available methods for rod and cone PDE6 enzymes purification from retina 
(Figure 19). Specific antibodies that detect cone PDE6 subunits are of specific 
need.
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Figure 19. Schematic presentation of the major strategies used to purify rod 
PDE6 and cone PDE6 enzymes from retina. 
Mono Q- anion-exchange chromatography using Mono G resin, HIC-hydrophobic 
interaction chromatography on butyl-Sepharose resin, HAP- hydroxyapatite 
chromatography, adapted from [269]. 
Homogenate
Crude extract Soluble extract (soluble rod 
PDE6 and cone PDE6)
Density gradient centrifugation
membrane associated 
rod PDE6
Hypotonic extraction
Rod PDE6
Mono Q HIC
Gel filtration
Q-Sepharose chromatography
Cone PDE6 Rod PDE6
HAP
Immunoaffinity purification
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(2) PDE6 is dedicated to high affinity specific hydrolysis of cGMP. Indeed, the 
retinal PDE6 enzyme operates with a very high catalytic efficiency for cGMP 
[kcat/KM = 4 × 108 M
−1s−1[211]. Are the low substrate affinity (KM = 20 μM for cGMP) 
and the high catalytic constant (Kcat up to 8000 cGMP hydrolyzed per sec) unique 
characteristics of retinal PDE6? Or lung PDE6 is subjected to a millisecond 
timescale activation as well? For getting an initial answer to that question rod and 
cone PDE6 enzymes isolated from human lung could be subjected to in vitro 
kinetic assay.
(3) Regarding PDE6 cGMP specificity, another interesting point would be to figure 
out which pool of cGMP synthesis PDE6 controls in the lung. It could be 
hypothesized that PDE6 is a part of the sGC pathway, particulate GC pathway, or 
both pathways. Such possibilities could be tested by using natriuretic peptides, 
which elevate cGMP via the particulate GCs and NO-donor like DEA-NO, which 
stimulates the sGC in cell culture models, where the catalytic subunits of PDE6 
(PDE6A, PDE6B and PDE6C) are genetically modified (siRNA silenced and/or 
overexpressed). 
(4) Another remaining issue is to characterize PDE6 expression pattern in mouse 
and rat lungs. It remains to be seen whether rodent lung expresses PDE6 enzyme 
subunits. A paucity of data exists on the degree of similarity/identity between 
rodent and human PDE6 enzymes, expressed from lung. The cellular and sub-
cellular localization of the PDE6 subunits in rodent lung is of further interest. Such
information will aid future studies aiming to characterize PDE6 subunits expression, 
regulation and function in animal models of pulmonary fibrosis.
(5) A number of approaches exist for inducing pulmonary fibrosis in animal models 
(Table VI). The most commonly used is the bleomycin model. This model is 
extensively studied in our group. Thus, further analysis of PDE6 subunits 
expression in bleomycin-challenged rodent lungs is of significant importance, so as 
to validate the noted regulation pattern of the PDE6 subunits in IPF-derived human 
lungs (Figure 13). It is worth mentioning, that the rat bleomycin model is of better 
value to study alterations in the alveolar epithelium, considering the significant 
similarities of alveolar structural remodeling (i.e. intra-alveolar buds formation,
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mural incorporation of collagen and obliteration of the alveolar space), observed in 
IPF lungs and bleomycin-challeged rat lungs [270].
Table VI. Approaches for inducing pulmonary fibrosis in animal models.
Exogenous Agent/Approach Nature of Tissue Damage Animal Species Used
Bleomycin Oxidant-mediated DNA scission 
leading to fibrogenic cytokine 
release
Mice, rats, hamsters, rabbits
Inorganic particles (silica, 
asbestos)
Type IV hypersensitivity reactions 
with or without granuloma
formation 
Mice, rats, hamsters, sheep, 
rabbits
Irradiation Free radical-mediated DNA 
damage
Mice, rats, rabbits, dogs,
hamsters, sheep, primates
Gene transfer (TGF-, IL-1, 
GM-CSF)
Downstream activation of specific 
cytokine pathway/s
Mice, rats
Fluorescein isothiocyanate Incompletely understood. 
Presumed T-cell-independent.
Mice
Vanadium pentoxide Incompletely understood. An 
inorganic metal oxide.
Mice, rats
Haptenic antigens (e.g. 
trinitrobenzene
sulphonic acid compounds)
Recall cell-mediated immune 
response 
Mice, hamsters
Adapted from [271].
(6) As a next step, one could consider the possibility of PDE6 targeted therapy for 
bleomycin-induced pulmonary fibrosis and perspectively for IPF. As a matter of a 
fact several classes of PDE inhibitors equally well inhibit PDE6 as the PDE family 
to which they are targeted. These effects are most prominent for the PDE5 family. 
Indeed, most of the PDE5-targeted drugs could be considered PDE5/6 inhibitors
(Table VII). Nevertheless, PDE5/6 inhibitors such as sildenafil, vardenafil, tadalafil, 
and zaprinast display different selectivity threshold for PDE5 and PDE6 [242, 272, 
273]. Sildenafil shows 9 folds selectivity for PDE5 over PDE6. Vardenafil is 15 fold 
more potent for PDE5 than for PDE6. Only, tadalafil [selectivity ratio of 210 (cone 
PDE6) or 640 (rod PDE6)] represents an authentic PDE5-selective inhibitor. 
Interestingly, zaprinast, a first generation PDE5-targeted inhibitor (which also 
weakly inhibits PDE1 with a 10-fold higher KI value), has 10-fold higher potency for 
PDE6 than for PDE5 (Table VII), and could be considered a “PDE6-selective” 
inhibitor [274, 275]. Thus, a goal of a future study could be to compare the effects 
of vardenafil and zaprinast on the development and progression of bleomycin-
induced lung fibrosis. The inhibitors’ effects could be estimated with respect to 
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survival rate, inflammation, collagen deposition and emphysema formation. It 
remains to be seen which inhibitor will have better effect. It could be evaluated as 
well whether the combination of vardenafil and zaprinast confers an additional 
beneficial effect. When assessing the effectiveness of PDE6 inhibition (cGMP 
hydrolysis) one should consider the calcium feedback mechanism this enzyme is 
subjected to (at least in the retina, Figure 10). PDE6 inhibitor ineffectiveness could 
be due to elevated intracellular calcium levels, resulting in GC inhibition. 
PDE5/6 inhibitors have been claimed to have side effects on photoreceptor viability 
and visual function [268]. These side effects, however, have been considered 
related to the systemical administration of the inhibitors. Moreover, Behn D et al.
have shown that sildenafil has a substantial side effects on retinal function in 
PDE6G knockout mice, but not in their wild type littermates [276]. Based on our 
findings mRNA transcripts of all PDE6 subunits are expressed from lung, including 
the inhibitory PDE6G and PDE6H subunits. Thus, it is reasonable to asume that 
inhibitor targeting therapy of lung PDE6 would not prove major adverse or 
irreversible side effects on retinal function, if any. 
Table VII. Efficacy and selectivity of PDE inhibitors to inhibit purified, 
activated bovine rod and cone PDE6.
Class Inhibitor PDE(X)
KI (nM)
a
PDE6 KI 
(nM)b
Rod
PDE6 KI 
(nM)b
Cone
6R/6C Selectivityc
6R/X
Selectivityc
6C/X
1 vinpocetine 11500 21000 ± 6100 13000 ± 
1200
1.6 1.8 1.1
8-Me-IBMX   3300 1600 ± 100 430 ± 30 3.7 0.5 0.1
2 EHNA 2500 28000 ± 2400 13000 ± 
1600
2.2 11 5
3 cilostamide 10 2800 ± 170 3400 ± 660 0.8 280 340
4 rolipram 490 28000 ± 620 22000 ± 
4000
1.3 57 45
YM 976 3.3 19000 ± 1500 5200 ± 630 3.7 5760 1580
5 tadalafil 3.3 2100 ± 150 700 ± 60 3.0 640 210
dipyridamole 580 480 ± 30 190 ± 14 2.5 0.8 0.3
T-1032  1.2 75 ± 12 26 ± 7 2.9 63 22
T-0156   23d 51 ± 4.0 61 ± 5 0.8 2.2 2.6
zaprinast   325 30 ± 3.0 32 ± 6 0.9 0.1 0.1
sildenafil  4.4 11 ± 1.0 4.7 ± 0.5 2.3 2.5 1.1
E4021   2.9 2.9 ± 0.5 2.9 ± 0.5 1.0 1.0 1.0
vardenafil  0.25 0.71 ± 0.06 0.3 ± 0.03 2.4 2.8 1.2
NS IBMX -- 4490 ± 804 1410 ± 453 3.2 -- --
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aAverage of KI values for each family of PDE obtained from the literature. IBMX is 
non-selective (NS); b The KI was determined from the equation: KI = IC50 (1+ 
[cGMP]/KM), where the IC50 was obtained from the dose-response curve for each 
inhibitor for rod and cone PDE6 and the KM values for bovine rod and cone PDE6 
are 14 μM or 7.0 μM, respectively; c Selectivity is defined as the ratio of the KI
values for the two indicated PDEs: 6R = rod PDE6; 6C = cone PDE6, and; X = 
PDE family 1 through 5; d Reported value is the IC50, because the KI value could 
not be calculated, adapted from [275].
(7) Identifying the expression of PDE isoforms in organs and cells that had not 
been reported previously is a subject gaining interest. Recently, PDE5 expression 
was reported in vascular, ganglion and bipolar cell layers of retinal tissue apart 
from the lung vasculature, and it was claimed to play a physiologic role in the retina 
and that there are PDE5 inhibitor-associated ocular side effects [277]. Importantly, 
the study of Foresta C et al. questions the differential expression pattern [211, 278, 
279] of PDE5 and PDE6 enzymes. Our report on lung PDE6 expression is of 
further support to this notion. As a matter of a fact PDE5 and PDE6 enzymes 
resemble not only in their (i) pharmacological properties [272], but show as well 
high similarity in their: (ii) amino acid sequence composition [280], (iii) strong 
preference for cGMP over cAMP as a substrate at the catalytic site [281], (iv) 
catalytic requirement for divalent cations, including high-affinity binding sites for 
zinc ions that likely serve a structural role as well [282, 283], (v) the presence of a 
γ-like protein that may associate with both enzymes [284, 285]. Thus, pending 
questions are: How the catalytic activities of these two closely related enzymes can 
be discriminated? What are the differences in the drug interaction sites within the 
catalytic domains of PDE5 and of the various PDE6 isoforms, expressed from 
lung? 
Catalytic site inhibitors: Rational drug design of compounds, which better 
discriminate PDE5 from PDE6, would require a deeper understanding of the 
molecular architecture of the active sites of PDE5 and rod/cone PDE6 enzymes, 
expressed from lung.
GAF domains manipulations: A particulary attractive option for discriminating 
between PDE5 and PDE6 may represent manipulation of cGMP binding to the 
regulatory domains in these two enzymes. Two types of functional ligands could be 
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designed to bind GAF domains: agonists and antagonists. Considering the 
differential regulation of PDE5 and PDE6 by cGMP. It can be imagined that agonist 
binding to the GAFa domain in PDE5 would result in permanent activation of the 
enzyme. Whereas agonist binding to the regulatory GAFa domain of PDE6 would 
result in an inactivation of the enzyme. And vice versa antagonizing cGMP binding 
to the GAFa domain in PDE5 should result in an enzyme inactivation. Whereas 
antagonizing cGMP binding to the GAFa domain in PDE6 should stimulate enzyme 
activity. Drug design at the GAFa domains might be a good strategy for attaining a 
higher selectivity pattern for PDE5 over PDE6 and vice versa than achieved with 
catalytic site inhibitors [286].
Rd mice: A plausibility to differentiate the roles of PDE5 and PDE6 enzymes in the 
lung is suggested by the study of Kuenzi F et al. [238]. The authors intelligently 
explored the options of a naturally occurring mutation in mice (rd mice) to study 
PDE6B function in the hippocampus. In rd mice, alterations in the PDE6B gene 
due to a single nonsense mutation (C to A transversion in codon 347) [287] and/or
an integration of provirus Xmv-28 [288], causes a PDE6 loss of activity. 
Interestingly, a hippocampal phenotype for the rd mutation has been identified. Rd 
mutation has been shown to decrease the number of interneurons and granule 
cells in the adult dentate gyrus [289]. Thus, it is tempting to postulate that rd mice 
would prove to have a lung phenotype as well. To further study the fuction of PDE6 
in the lung one could compare the responses of rd/rd and wild-type mice to 
relatively selective PDE5 and PDE6 inhibitors, i.e. vardenafil and zaprinast. Similar 
experimental settings could be utilized to study PDE6 contributions to pulmonary 
fibrosis, i.e. one could compare the pulmonary characteristics of rd/rd and wild type 
bleomycin-treated mice. PDE5/6 inhibitory studies could be undertaken in such 
scenario as well.
Knockout animal models: In addition to the naturally occurring rd mutation, 
investigations using mice with tissue-specific conditional gene disruption and RNA 
interference might be the best feasible option to probe lung PDE5 and PDE6 
activities and validate inhibitors’ targets. For example, by using the Cre-loxP site-
specific recombination system, tissue-specific mouse mutants could be generated 
in which PDE5 protein is ablated in ATII cells (Cre recombinase under Pro-SPC/ 
CC10 promoters). It could be imagined that evaluating PDE5/6 inhibitors in such 
conditional inactivation of PDE5 would give unbiased information about PDE6 
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functionality in the alveolar epithelium. What would be the responses of such 
knockout mice to bleomycin treatment is another interesting point. 
(8) In the retina, both Nrl and Crx are required for full transcriptional activity of the 
PDE6A gene [290], whereas Sp proteins have been implicated in the 
transcriptional regulation of the PDE6B gene [291, 292]. Characterization the 
promoter regions of PDE6 catalytic subunits, expressed from lung is an important 
issue. Do Nrl and Crx transactivate lung PDE6A promoter? Are Sp proteins 
involved in transactivation of lung PDE6B promoter? Or does the lung itself 
possess unique factors that control the transcription of the PDE6 catalytic 
subunits? To address such questions one should consider that promoter regions of 
genes that are transcriptionally active are often demarcated by a DNase I-
accessible open chromatin region. Thus, to assess the chromatin status of the 
region around the PDE6A and PDE6B promoter region in vivo, a DNase I 
hypersensitivity assay could be performed with A549 cells, which transcribe 
PDE6A and PDE6B mRNAs (Figure 15c). To further delimit the core promoter
regions of PDE6A and PDE6B, luciferase reporter gene constructs containing 
varying lengths of PDE6A/B promoter regions could be assayed by transient
its are expressed in human ATII cells.  PAGEREF _Toc213403314 \h 59
Fassay (EMSA) can be used to determine the relative binding strength of each 
potential promoter binding site. 
Gaining such information will aid future studies aiming to delinate cone and rod 
PDE6-specific functions in the lung. For example, the Nrl (-/-) mouse is a promising 
mouse model for the investigation of cone function. This is so because, the 
developing Nrl (-/-) retina produces no rods [293]; rather, it is populated with 
photoreceptors exhibiting ultrastructural, histochemical, molecular, and kinetic
features that support the hypothesis that they are indeed cones [294]. It remains an 
open possibility to see whether such scenario could be applied in the context of the 
lung.
(9) PDE6 is known for the fact that it undergoes numerous post-translational 
modifications resulting in carboxymethylation and isoprenylation of the C-terminus 
of the catalytic subunits. The incorporation of a farnesyl group (PDE6A subunit) or 
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a geranylgeranyl group (PDE6B) accounts for the high-affinity interaction of rod 
PDE6 with photoreceptor membranes [252, 295]. The PDE6G also acts as a 
substrate for phosphorylation at several distinct sites, i.e. PDE6G phosphorylation
at Thr (22) or Thr (35) has little effect on the PDE6 holoenzyme itself, but greatly 
diminishes the ability of activated transducin to bind the PDE6G subunit and relieve 
inhibition of catalysis [296]. PDE6G phosphorylation at Thr (62) in human 
embryonic kidney 293 cells has been reported to regulate mitogenic signaling [244]. 
Scarcity of data exists on potential regulation of PDE6 catalytic subunits by
phosphorylation. Further research should opt to characterize the posttranslational 
modifications the lung PDE6 enzymes might be subjected to (phosphorylation, 
farnesylation, geranyl-geranylation, methylation etc.). 
(10) Characterization of PDE6 subunits expression and function in other pulmonary 
disease models could be of particular interest as well. We currently lack knowledge 
of the prevalence and functions of PDE6 in pulmonary vasculature, endothelium 
and in other tissues of the lung. For example, a goal of a future study could be to 
characterize PDE6 subunits expression profile in monocrotaline and hypoxia–
induced pulmonary hypertension models. These models are well characterized in 
our group [297, 298]. Plausible beneficial effects of PDE6 inhibition (zaprinast) on 
pulmonary hemodynamics, pulmonary vascular remodeling, and survival could be 
anticipated. PDE5 and PDE6 roles in such models could be compared as well 
(inhibitory studies with vardenafil, sildenafil, zaprinast). 
(11) One of the salient findings of this study was that PDE6D have a role in ATII 
cells proliferation. The challenge remains, however, to confirm PDE6D functionality 
in vivo. It could be interesting to see the responses of PDE6D (-/-) mice [266] to 
bleomycin treatment. However, the best feasible option to study PDE6D function in 
vivo would be to generate tissue-specific mouse mutants in which the PDE6D 
protein is ablated in ATII cells (Cre recombinase under Pro-SPC/ CC10 promoters)
and study the responses of such mice to bleomycin treatment. It remains to be 
seen whether such mice would develop more severe pulmonary fibrosis. In that line, 
it is tempting to further speculate that PDE6D overexpression in animal models of 
pulmonary fibrosis (bleomycin etc.) may be beneficial to boost up alveolar re-
epithealization and reduce or reverse the development of pulmonary fibrosis.
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VI. Appendix
Table I. Classification and contrasting histological features of IIPs.
Clinical presentation IPF/CFA NSIP RB-ILD DIP AIP LIP COP
Histopathological 
pattern
UIP NSIP RB DIP AIP LIP COP
Distribution patchy 
(periphery of the 
acinus or lobule)
diffuse patchy 
(bronchiolocentric)
diffuse diffuse diffuse patchy
(centrilobular)
Spatio-temporal 
appearance
heterogeneous homogeneous homogeneous homogeneous homogeneous homogeneous homogeneous
Interstitial 
inflammation
scanty prominent in 
cellular pattern
scanty
(peribronchiolar)
scanty scanty prominent scanty
Collagen fibrosis patchy prominent in 
fibrotic pattern
variable, if any, mild 
and
peribronchiolar
variable, if any, 
diffuse
_ rare rare
Fibroblast proliferation prominent, but 
focal (FF)
prominent and 
diffuse in fibrotic 
pattern, rare FF
_ _ prominent and 
diffuse (no FF)
_ intra-alveolar 
prominent and 
patchy (Masson’s 
bodies)
OP foci Rare occasional _ _ _ rare +
Intra-alveolar 
macrophage 
accumulation
Focal occasional peribronchiolar diffuse _ occasional, mild _
IPF idiopathic pulmonary fibrosis, CAF cryptogenic fibrosing alveolitis, UIP usual interstitial pneumonia, NSIP non-specific interstitial pneumonia, RB-ILD 
respiratory bronchiolitis-associated interstitial lung disease, DIP desquamative interstitial pneumonia, AIP acute interstitial  pneumonia, LIP lymphoid 
interstitial pneumonia, COP cryptogenic organizing pneumonia, FF fibroblastic foci, OP organizing pneumonia, summerized from [299, 300]
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Table II. Properties of cyclic nucleotide PDE families. 
Gene Family Descriptive name Substrate specificity Regulation Tissue expression Intracellular 
localization
Inhibitors
PDE1A (1-4)
PDE1B (1)
PDE1C (1-6)
Ca2+/CAM stimulated 
PDE
cAMP < cGMP
cAMP < cGMP
cAMP & cGMP
(+) Ca2+/CAM
(-) PKA, CamKII
Brain, heart, smooth
muscle, olfactory 
cilia, testis
cytosolic 8-Methoxymethyl 
IBMX, Vinpocetine, 
SCH-51866
PDE2A (1-3) cGMP-stimulated PDE cAMP & cGMP (+) cGMP, PKC
(+/-) N terminal 
targeted domain
Adrenal cortex,
brain, heart
PDE2A2, PDE2A3 
membrane-bound, 
PDE2A1 cytosolic
EHNA, Trequinsin
PDE3A (1)
PDE3B (1)
cGMP-inhibited PDE cAMP > cGMP (+) PKA, PKB
(-) cGMP
(+/-) N-terminal
targeting domain
Heart, adipose
tissue, pancreas,
platelets
Membrane-bound or 
cytosolic depending 
on the splice variant 
and the cell type it is 
expressed in
Cilostamide,
Cilostazol, 
Enoximone,
Imazodan,
Milrinone,
Trequinsin
PDE4A (1-7)
PDE4B (1-2)
PDE4C (1-4)
PDE4D (1-6)
cAMP-specific PDE cAMP (+) PKA, ERK,
Phosphatidic Acid
(-) ERK, Caspases
(+/-) N-terminal
targeting domains
Inflammatory cells,
Lung, testis (human)
Membrane-bound
Cytosolic or 
particulate fractions
Rolipram, YM976
PDE5A (1-3) cGMP-specific PDE cGMP (+) cGMP, PKG, 
PKA
(-) Caspases
Lung, platelets, 
smooth
muscle, Corpus
cavernosum
cytosolic Dipyridamole, 
DMPPO,
Sildenafil, T-0156, T-
1032, Tadalafil,
Vardenafil, Zaprinast
PDE6A (1)
PDE6B (1)
PDE6C (1)
PDE6D (1)
PDE6G (1)
PDE6H (1)
Photoreceptor cGMP-
specific PDE
cGMP (+) Transducin 
(-) cGMP, PDE6D 
and PDE6G/H
Rod and cone
photoreceptor 
outer segments
Targeted to the 
membrane by 
isoprenylation 
Cytosolic by virtue 
of its association 
with the PDE6D 
subunit
Dipyridamole, 
Sildenafil,
Tadalafil, 
Vardenafil,
Zaprinast
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PDE7A (1-3)
PDE7B
cAMP-specific PDE cAMP (+/-) PKA Skeletal muscle, T-
cells, B-cells
cytosolic Dipyridamole
PDE8A
PDE8B
cAMP-specific PDE cAMP PAS domain Testis, liver, kidney
Eye (human)
Cytosolic or 
particulate fractions
Dipyridamole
PDE9A (1-4) cGMP-specific PDE cGMP Kidney, liver (human) PDE9A5 cytosolic, 
PDE9A1 nucleous
Sildenafil, Zaprinast
PDE10A (1-2) cAMP-inhibited cGMP 
PDE
cAMP < cGMP (-) cAMP Brain, testis (rat)
Multiple (human)
Dipyridamole
PDE11A (1-4) Dual specific cGMP 
binding PDE
cAMP and cGMP Skeletal muscle, 
testis, prostate 
(human)
cytosolic Zaprinast, 
dipyridamole, tadalafil
EHNA erythro-9-(2-hydroxy-3-nonyl)adenine, IBMX 3-isobutyl-1-methylxanthine, Ca2+/CAM calcium/calmodulin, Summerized from [301, 302].
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Table III. Gene specific primer sequences and RT-PCR conditions.
gene 
(bp)
Primers (5’3’)
Gene accession 
number
Annealing 
T (°C)
# of 
cycles
Extension 
time (min)
PDE1A
(240)
F-ctggttggcttctacctttacac
R-ctatgctctccacttgcttcatt
NM_001003683 58 35 1
PDE1B
(199)
F-acattctctgtgctgactgacg
R-ccttccatttctgcttattctcc
NM_000924 58 35 1
PDE1C
(222)
F-gtcacttccaacaaatcaaagc
R-ggtcacacagaggagaaaaagg
NM_005020 58 35 1
PDE5A
(245)
F-ctattccctgttccttgtctgtg
R-tgctttgtgtcttgtagcctgta
AY264918 58 35 1
PDE9A
(193)
F-acctgatgggttcaagcagat
R-tggacggacctcgttagagata
AF067226 58 35 1
PDE10A
(207)
F-gagatgaacgatttccaagagg
R-gaccctgatgtattgctactgaa
NM_006661 58 35 1
PDE11A
(203)
F-actgtgtaggtggcttttgaca
R-cattgttggttcccctgtg
NM_016953 58 35 1
PDE6A
(176)
F-tggcaaagaggacatcaaagt
R- taatcatccatccagactcatcc
NM_000440 58 35 1
PDE6B 
(163)
F-gcagaacaataggaaagagtgga
R-caggatacagcaggttgaagact
NM_000283 58 35 1
PDE6C 
(240)
F-aagaatgttttgtccctgccta
R-aagagtggctttggtttggtt
NM_006204 58 35 1
PDE6D 
(248)
F-ggatgctgagacagggaagata
R-gccaggtatttgtggagttagg
NM_002601 58 35 1
PDE6G
(230)
F-gacagaccaggcagttcaagag
R-tgagcagggtttagagcacagt
NM_002602 58 35 1
PDE6H 
(141)
F-gacaacactactctgcctgctc
R-gtcatctccaaatcctttcacac
NM_006205 58 35 1
GAPDH 
(461)
F-caccgtcaaggctgagaac
R-cagtagaggcagggatgatgtt
M33197 56 35 1
β Actin
(424)
F-actcttccagccttccttcct
R-gccaatctcatcttgttttctg
M33197 56 35 1
PDE6D 
(452) 
F-accagagtgagaaagccg
R- cagtttcctcctccctccaa
NM_002601 60 35 3
Pro-SPC 
(191)
F-gaggctctcaatagaaaagtccac
R-ctagatgtagtagagcggcacct
NM_003018 59 30 1
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Table IV. Primers used for cloning.
Gene Primers (5’3’) Plasmid Aplication
PDE6D
(452)
F- accagagtgagaaagccg
R- cagtttcctcctccctccaa
pGEMT-easy cloning
PDE6D
(452)
F- caccatgtcagccaaggac
R- aacatagaaaagtctcactctgga
pcDNA 3.1 cloning
T7 F- taatacgactcacattaggg
pGEMT-easy
pcDNA 3.1
sequencing
SP6 R- tatttaggtgacactatag pGEMT-easy sequencing
BGH 
R- tagaaggcacagtcgagg pcDNA 3.1 sequencing
Table V. Characteristics of IPF patients with UIP pattern.
No Diagnosis Gender Age 
(yr)
Ex-
smoker
Current 
smoker
FEV1
(%)
FVC 
(%)
TLCOSB
(%)
TLCO/VA 
(%)
1 IPF (UIP) male 58 yes no 63 55 na na
2 IPF (UIP) male 23 yes no 61 56 29 39
3 IPF (UIP) male 65 no no 40 32 27 58
4 IPF (UIP) female 42 no no 53 50 na na
5 IPF (UIP) male 68 no no 37 41 17 35
6 IPF (UIP) female 62 no no 37 34 32 74
7 IPF (UIP) female 66 yes no 75 48 na na
8 IPF (UIP) male 56 yes no 32 35 29 na
9 IPF (UIP) male 63 yes no 47 44 na na
10 IPF (UIP) female 54 yes no 40 33 na na
FEV= forced expiratory volume, FVC= forced vital capacity, TLCO= carbon monoxide 
lung transfer factor, SB= single breath, VA= alveolar volume,
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Figure A1. pGEM-T vector circle map and sequence reference points.
Inserts can be sequenced using the SP6 promoter primer, T7 promoter primer, 
pUC/M13 forward primer, or pUC/M13 reverse primer. A single digest with BstZI 
(will release inserts cloned into the pGEM-T Vector.
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Figure A2. Structure of pcDNA3.1/V5-His-TOPO expression vector and 
sequence reference points.
The figure summarizes the features of the pcDNA3.1/V5-His-TOPO vector. The 
vector is supplied linearized between base pairs 953 and 954. This is the TOPO 
cloning site.
Figure A3. Principle of directional TOPO cloning protocol.
Taq polymerase has a nontemplate-dependent terminal transferase activity that 
adds a single deoxyadenosine (A) to the 3  ´ends of PCR products. The linearized 
vector has single, overhanging 3  ´ deoxythymidine (T) residues. This allows PCR 
inserts to ligate efficiently with the vector. Topoisomerase I from Vaccinia virus
binds to duplex DNA at specific sites and cleaves the phosphodiester backbone 
after 5′-CCCTT in one strand [303]. The energy from the broken phosphodiester 
backbone is conserved by formation of a covalent bond between the 3′ phosphate 
of the cleaved strand and a tyrosyl residue (Tyr-274) of topoisomerase I. The 
phospho-tyrosyl bond between the DNA and enzyme can subsequently be 
attacked by the 5′ hydroxyl of the original cleaved strand, reversing the reaction 
and releasing topoisomerase [304]. TOPO cloning exploits this reaction to 
efficiently clone PCR products.
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